Phase IIa Open-label Clinical Study of Intratumoural Administration of BO-112 in Combination With Pembrolizumab in Subjects With Liver Metastasis From Colorectal Cancer or Gastric/Gastro-oesophageal Junction Cancer
Phase: PHASE2
Conditions: Colorectal Cancer, Gastric Cancer, Oesophageal Cancer
Sponsor: Highlight Therapeutics

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 1 of 99 
 
Protocol Title: 
 
Phase IIa open-label clinical study of intratumoural administration of BO-112 
in combination with pembrolizumab in subjects with liver metastasis from 
colorectal cancer or gastric/gastro-oesophageal junction cancer 
 
 
Protocol Number:   
BOT112-02 
Version:  
 
 
 Version 2.2 
Product:  
 
 
BO-112 
 
Short Title:  
Study of BO-112 with pembrolizumab for colorectal or gastric/GEJ 
cancer with liver metastasis 
 
Study Phase:   
 
IIa 
 
Sponsor Name:  
 
Highlight Therapeutics, S.L. 
Sponsor Legal Address:  
Parc Científic Universitat de Valencia 
C/ Catedrático Agustín Escardino, 9 
46980 Paterna (Valencia) SPAIN 
 
Eudra CT Number:  
2019-004624-38 
 
Date of Protocol:  
 
05 Dec 2019 Initial Version 1.0 
 
 
 
 
15 May 2020 Version 2.0 
 
 
 
 
25 Sep 2020 Version 2.1 
 
 
 
 
15 Oct 2021 Version 2.2 
 
 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 2 of 99 
Important contact information: 
 
SAE reporting  
• 
Email: drugsafety@pivotalcr.com 
• 
SAEs Fax line (Europe): +34 91 307 60 47  
 
Medical Monitor  
• 
Email: BOT112-02medicalmonitoring@pivotalcr.com   
• 
Telephone number (Europe): +34 91 708 12 50 
Sponsor Signatory: 
 
I have read this protocol in its entirety and agree to conduct the study accordingly: 
 
 
 
 
 
 
 
 
Vanesa Pons MD, PhD 
Medical Director 
 
Date 
 
 
 
 
 
 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 3 of 99 
 
TABLE OF CONTENTS 
TABLE OF TABLES ...............................................................................................................6 
TABLE OF FIGURES .............................................................................................................7 
1.0 
PROTOCOL SUMMARY ..........................................................................................8 
1.1 
Synopsis .............................................................................................................8 
1.2 
Schema ............................................................................................................14 
1.3 
Schedule of Activities .....................................................................................15 
2.0 
INTRODUCTION......................................................................................................18 
2.1 
Study Rationale ..............................................................................................18 
2.2 
Background ....................................................................................................20 
2.2.1 
Nonclinical Studies ............................................................................21 
2.2.2 
Clinical Studies ..................................................................................22 
2.3 
Benefit/Risk Assessment ................................................................................24 
3.0 
OBJECTIVES AND ENDPOINTS ..........................................................................26 
4.0 
STUDY DESIGN ........................................................................................................27 
4.1 
Overall Design ................................................................................................27 
4.2 
Scientific Rationale for Study Design ...........................................................28 
4.3 
Justification for Dose .....................................................................................29 
4.4 
End of Study Definition .................................................................................30 
5.0 
STUDY POPULATION ............................................................................................31 
5.1 
Inclusion Criteria ...........................................................................................31 
5.2 
Exclusion Criteria ..........................................................................................32 
5.3 
Lifestyle Considerations ................................................................................33 
5.4 
Screen Failures ...............................................................................................34 
6.0 
STUDY TREATMENT .............................................................................................35 
6.1 
Study Treatment(s) Administered ................................................................35 
6.2 
Treatment Continuation Decisions Based on Efficacy ...............................38 
6.3 
Dose Modification ..........................................................................................38 
6.3.1 
Dose Modification and Toxicity Management for Immune-
related TEAEs ...................................................................................38 
6.3.2 
Temporary Discontinuation/Interruption ...........................................42 
6.4 
Preparation/Handling/Storage/Accountability ...........................................42 
6.5 
Measures to Minimise Bias: Randomisation and Blinding ........................43 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 4 of 99 
6.6 
Study Treatment Compliance .......................................................................44 
6.7 
Concomitant Therapy ....................................................................................44 
6.8 
Treatment after the End of the Study ..........................................................44 
7.0 
DISCONTINUATION OF STUDY TREATMENT AND SUBJECT 
DISCONTINUATION/WITHDRAWAL ................................................................45 
7.1 
Discontinuation of Study Treatment ............................................................45 
7.1.1 
Permanent Discontinuation ...............................................................45 
7.1.2 
Rechallenge .......................................................................................45 
7.2 
Subject Discontinuation/Withdrawal from the Study ................................46 
7.3 
Lost to Follow-up ...........................................................................................46 
8.0 
STUDY ASSESSMENTS AND PROCEDURES ....................................................47 
8.1 
Efficacy Assessments .....................................................................................47 
8.2 
Safety Assessments .........................................................................................50 
8.2.1 
ECOG Performance Status ................................................................50 
8.2.2 
Physical Examinations .......................................................................50 
8.2.3 
Vital Signs .........................................................................................50 
8.2.4 
Electrocardiograms ............................................................................51 
8.2.5 
Clinical Safety Laboratory Assessments ...........................................51 
8.3 
Adverse Events ...............................................................................................51 
8.3.1 
Time Period and Frequency for Collecting AE and SAE 
Information ........................................................................................52 
8.3.2 
Method of Detecting AEs and SAEs .................................................53 
8.3.3 
Follow-up of AEs and SAEs .............................................................53 
8.3.4 
Regulatory Reporting Requirements for SAEs .................................53 
8.3.5 
Pregnancy ..........................................................................................53 
8.3.6 
Events of Clinical Interest .................................................................53 
8.3.7 
Disease-related Events and/or Disease-related Outcomes Not 
Qualifying as SAEs ...........................................................................54 
8.4 
Treatment of Overdose ..................................................................................55 
8.5 
Pharmacokinetics ...........................................................................................55 
8.6 
Pharmacodynamics ........................................................................................56 
8.7 
Genetics ...........................................................................................................56 
8.8 
Biomarkers .....................................................................................................56 
8.8.1 
Immune Cell Profile of the Tumour Microenvironment ...................56 
8.8.2 
DNA Research ...................................................................................56 
8.9 
Health Economics OR Medical Resource Utilisation and Health 
Economics .......................................................................................................57 
9.0 
STATISTICAL CONSIDERATIONS .....................................................................58 
9.1 
Statistical Hypotheses and Sample Size Determination .............................58 
9.2 
Populations for Analyses ...............................................................................59 
9.3 
Statistical Analyses.........................................................................................59 
9.3.1 
Efficacy Analyses ..............................................................................60 
9.3.2 
Safety Analyses .................................................................................61 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 5 of 99 
9.3.3 
Other Analyses ..................................................................................62 
9.3.4 
Missing, Unused and Spurious Data .................................................62 
9.4 
Interim Analyses ............................................................................................62 
9.5 
Data Monitoring Committee .........................................................................62 
10.0 
REFERENCES ...........................................................................................................64 
11.0 
APPENDICES ............................................................................................................68 
Appendix 1 
Abbreviations ...................................................................................69 
Appendix 2 
Regulatory, Ethical, and Study Oversight Considerations ..........72 
Regulatory and Ethical Considerations ............................................................72 
Financial Disclosure.........................................................................................72 
Insurance ..........................................................................................................73 
Informed Consent Process ...............................................................................73 
Data Protection.................................................................................................73 
Administrative Structure ..................................................................................74 
Dissemination of Clinical Study Data..............................................................74 
Data Quality Assurance ...................................................................................74 
Source Documents ...........................................................................................75 
Study and Study Center Closure ......................................................................75 
Publication Policy ............................................................................................76 
Appendix 3 
Clinical Laboratory Tests ...............................................................77 
Appendix 4 
Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow-up, and Reporting .....................................78 
Appendix 5 
Excluded Medications/Therapy .....................................................82 
Appendix 6: Description of the iRECIST Process for Assessment of 
Disease Progression ........................................................................................83 
Appendix 7 
Contraceptive Guidance and Collection of Pregnancy 
Information .....................................................................................................87 
Appendix 8 
Eastern Cooperative Oncology Group 
(ECOG)Performance Status .........................................................................90 
Appendix 9     Recommendations for cancer patient management in the 
protocol BOT112-02 during SARS-CoV-2 pandemic .................................91 
Appendix 10 
Signature of Investigator ................................................................99 
 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 6 of 99 
TABLE OF TABLES 
Table 1 
Schedule of Assessments .................................................................................15 
Table 2 
Study Objectives and Endpoints ......................................................................26 
Table 3 
Pembrolizumab Infusion Reaction Dose Modification and Treatment 
Guidelines ........................................................................................................36 
Table 4 
Study Treatment Details ..................................................................................38 
Table 5 
Dose modification and toxicity management guidelines for irAEs 
associated with pembrolizumab .......................................................................39 
Table 6 
Imaging and Treatment after First Radiologic Evidence of Progressive 
Disease .............................................................................................................48 
Table 7 
Analysis Sets ....................................................................................................59 
Table 8 
Efficacy Analyses ............................................................................................60 
Table 9 
Study Administrative Structure – 3rd parties external to Sponsor....................74 
Table 10 
Protocol-required Safety Laboratory Assessments ..........................................77 
 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 7 of 99 
TABLE OF FIGURES 
Figure 1 
Study Schema...................................................................................................14 
 
 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 8 of 99 
1.0 PROTOCOL SUMMARY 
1.1 
Synopsis 
Protocol Title: Phase IIa open-label clinical study of intratumoural administration of BO-112 in 
combination with pembrolizumab in subjects with liver metastasis from colorectal cancer or gastric/gastro-
oesophageal junction cancer. 
Short Title: Study of BO-112 with pembrolizumab for colorectal or gastric/GEJ cancer with liver 
metastasis. 
Rationale: 
Checkpoint inhibition provides significant clinical benefit in various types of cancer, with blockade of the 
programmed cell death protein 1(PD1) receptor and its ligands being the most widely used approach. Some 
tumours, however, evade the immune system and are not, or only poorly, responsive to checkpoint 
inhibition. The innate immune system interacts with the adaptive immune system and responds to different 
triggers. The purpose of this study is to evaluate if the combination of activation of the innate immune 
system and blockade of the PD1 immune checkpoint can provide clinical benefit in patients with tumours 
that are poorly, or only moderately responsive to monotherapy with an anti-PD1 agent. Activation of the 
innate immune system will be via direct intratumoural (IT) administration of BO-112. Checkpoint 
inhibition will be via intravenous infusion of pembrolizumab. Metastatic liver lesions have been selected 
as the site for intratumoural injection for 2 reasons: to reduce the variability of the microenvironment of the 
injection site, and to evaluate if the TLR3 agonist activity of BO-112 potentially breaks through the 
generally immune-tolerant hepatic microenvironment. 
 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 9 of 99 
Study Objectives and Endpoints 
Objectives 
Endpoints 
Primary 
 
• 
Investigation of the anti-tumour efficacy and safety 
of repeated IT administrations of BO-112 in 
metastatic liver lesions in combination with IV 
pembrolizumab 
• 
Efficacy: ORR based on the BOR using 
RECIST 1.1 
• 
Safety: number and proportion of subjects with 
study treatment-related TEAEs with severity 
≥ Grade 3 (NCI-CTCAE v 5.0) 
 
Secondary 
 
• 
Further characterisation of safety and of clinical 
activity of the combination as well as 
determination of systemic exposure of BO-112 
• 
Safety: number and proportion of subjects with 
TEAEs (any grade) 
• 
Safety: number and proportion of subjects with 
related TEAEs (any grade) 
• 
Tolerability: number of study discontinuations due 
to related TEAE 
• 
Efficacy: disease control rate (DCR = CR, PR and 
SD of at least 12 weeks duration) using 
RECIST 1.1 
• 
Efficacy: ORR based on best overall response 
using RECIST modified for immune-based 
therapies (iRECIST) 
• 
Efficacy: DCR = iCR, iPR + iSD of at least 
12 weeks duration) using iRECIST 
• 
Efficacy: duration of response 
• 
Efficacy: progression-free survival 
• 
Efficacy: overall survival rate at 6 months 
• 
Pharmacokinetics: systemic exposure after first 
BO-112 administration 
 
Exploratory 
 
• 
Evaluation of antitumoural and immunological 
effects in the TME of the injected lesion. 
• 
Immune cell profile of TME in injected and 
noninjected lesions 
• 
Genetic analysis of the TME 
Abbreviations: BOR=best overall response; CR= complete response; DCR=disease control rate; iRECIST= 
RECIST modified for immune-based therapies; IT=intratumoural; NCI-CTCAE=National Cancer Institute-
Common terminology criteria for adverse events; ORR=objective response rate; PR= partial response; 
RECIST= Response evaluation criteria in solid tumours; SD=stable disease; TEAE=treatment-emergent 
adverse event; TME=tumour microenvironment. 
Note: the prefix “i” denotes immune-related or immune-based. 
 
 
 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 10 of 99 
Overall Design: 
This is an open-label, Phase II, non-comparative, 2-cohort study with a Simon’s 2-stage design. 
Cohort A: colorectal cancer (CRC) 
Cohort B: gastric or gastro-oesophageal junction cancer (GC/GEJ) 
Subjects will be enroled in each cohort for Stage 1 of the study up to the predefined sample size and treated 
according to the treatment schedule. Enrolment will be suspended per cohort and a Data Monitoring 
Committee (DMC) will review the safety and efficacy data available at the time that the last subject enroled 
has reached the first on-study response assessment at Week 7 (= Cycle 3). The DMC will make a 
recommendation to the Sponsor for each cohort regarding expanding to the total foreseen sample size. 
Treatment Scheme
 
Abbreviation: W=week; IT=intratumoural; IV=intravenous 
 
Eligibility 
Inclusion Criteria 
Subjects are eligible to be included in the study only if all of the following criteria are met: 
1. Be willing and able to give written informed consent for the study. 
2. Be  18 years of age on day of signing informed consent. 
3. Have nonresectable liver metastasis(es) of colorectal or gastric/gastro-oesophageal junction cancer 
(GC/GEJ). History of resection for liver metastasis is allowed. 
4. Have histological or cytological proof of colorectal (Cohort A) or GC/GEJ cancer (Cohort B). 
5. Have progressed during or after, or have not tolerated therapy for advanced/metastatic disease as 
follows: 
a. 
Cohort A (CRC): at least 2 lines of fluoropyrimidine, irinotecan and/or oxaliplatin containing 
therapy with or without bevacizumab according to institutional practice; if epidermal growth 
factor receptor (EGFR) positive/RAS wild type, prior anti-EGFR treatment is required. In 
case of prior resection of hepatic metastasis with hepatic recurrence, only 1 prior line of 
fluoropyrimidine, irinotecan and/or oxaliplatin containing therapy is required. 
b. 
Cohort B (GC/GEJ): fluoropyrimidine and platinum containing treatment; if Human 
epidermal growth factor receptor 2 (HER-2) positive, also prior anti-HER-2 treatment is 
required. 
6. Have at least 1 liver metastasis of minimum 20 mm in diameter that is suitable for percutaneous, IT 
injection (including, but not limited to, absence of tumour infiltration into the main portal vein, hepatic 
vein or vena cava). Recurrence in the liver of previously resected liver metastasis is allowed. 
7. Presence of at least 1 measurable lesion according to RECIST v1.1. Note: this may be the liver 
metastasis selected for injection if it is the only measurable lesion present. 
8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 11 of 99 
9. Adequate haematologic and end-organ function defined by the following laboratory results obtained 
within 2 weeks prior to the first dose of study treatment: 
a. ANC ≥ 1.5 × 109/L 
b. Platelet count ≥ 100 × 109/L  
c. Haemoglobin ≥ 9.0 g/dL 
d. AST and ALT  5 × upper limit of normal (ULN) 
e. Serum total bilirubin  2 × ULN (if known Gilbert’s syndrome, serum bilirubin level  3 × ULN) 
f. Prothrombin time (PT) (or international normalised ratio [INR]) within normal limits and activated 
partial prothrombin time (aPTT) within normal limits 
g. Serum albumin ≥ 2.5 g/dL 
h. Serum creatinine  1.5 × ULN or creatinine clearance ≥ 30 mL/min (calculated per Cockroft-Gault 
formula) 
10. Female subjects who are not pregnant or breastfeeding and at least 1 of the following conditions applies: 
a) Not a woman of childbearing potential (WOCBP)  
b) WOCBP who agrees to follow contraception guidance during the treatment period and for at least 
120 days after the last dose of study treatment. 
11. Able and willing to comply with study and follow-up procedures. 
Exclusion Criteria 
Subjects are excluded from the study if any of the following criteria apply: 
1. Prior treatment with an anti-PD1, anti-PDL1 or anti-PDL2 agent, an agent directed to another 
stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX40, CD137) or any Toll-like receptor 
(TLR) agonist. 
2. Liver metastasis(es) with macroscopic tumour infiltration into the main portal vein, hepatic vein or 
vena cava. 
3. Contraindications to tumour biopsy and injections of the hepatic metastasis(es), such as coagulopathy, 
therapeutic dose anticoagulant treatment and treatment with long-acting agents such as clopidogrel 
which cannot be safely stopped. 
4. Chemotherapy, definitive (curative) radiation, or biological cancer therapy within 4 weeks prior to the 
first dose of study treatment. Note: Participants must have recovered from all adverse events (AEs) due 
to previous therapies to ≤ Grade 1 or baseline. Participants with ≤ Grade 2 neuropathy may be eligible. 
5. Palliative radiotherapy (≤ 2 weeks of radiotherapy) within 1 week of start of study treatment. Subjects 
must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had 
radiation pneumonitis. 
6. Clinically active central nervous system (CNS) metastases and/or carcinomatosis meningitis. Subjects 
with previously treated brain metastases may participate provided they are radiologically stable, ie, 
without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging 
should be performed during study screening), clinically stable and without requirement of steroid 
treatment for at least 14 days prior to first dose of study treatment. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 12 of 99 
7. History of a second malignancy, unless potentially curative treatment has been completed with no 
evidence of malignancy for 2 years. 
8. Life expectancy of < 12 weeks. 
9. Severe hypersensitivity ≥ Grade 3 to pembrolizumab and/or any of its excipients. 
10. Active infection requiring systemic therapy. 
11. History of (non-infectious) pneumonitis that required steroids or current pneumonitis. 
12. Active autoimmune disease that required systemic treatment in past 2 years (ie, with use of disease 
modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, 
insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not 
considered a form of systemic treatment and is allowed. 
13. Receiving systemic immunosuppressive therapy within 28 days before enrolment with the exceptions 
of intranasal, topical, and inhaled corticosteroids or oral corticosteroids at physiological doses not 
exceeding 10 mg/day of prednisone or equivalent. 
14. Known human immunodeficiency virus (HIV) infection. 
15. Known history of hepatitis B (defined as HbsAg reactive) or known active hepatitis C (defined as HCV 
RNA [qualitative] detected) virus infection. 
16. For WOCBP: pregnancy or a positive urine pregnancy test (eg within 72 hours) prior to treatment; or 
breastfeeding. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test 
will be required. 
17. Any other medical condition which would impact the safety of the subject or interfere with the subject’s 
ability to comply with the study and follow-up procedures, in the opinion of the investigator. 
18. Has received a live vaccine within 28 days prior to the first dose of study drug. Examples of live 
vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster 
(chicken pox), yellow fever, rabies, Bacillus Calmette–Guérin (BCG), and typhoid vaccine. Seasonal 
influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal 
influenza vaccines are live attenuated vaccines and are not allowed. 
19. Is currently participating or has participated in a study of an investigational agent or has used an 
investigational device within 4 weeks prior to the first dose of study treatment (subjects who are in a 
follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last 
dose of the previous investigational agent). 
20. Has had an allogenic tissue/solid organ transplant 
Number of Investigators and Study Centers: 
Approximately 15 Investigators and 15 study centers in 4 European countries are expected to participate in 
this study. 
 
Number of Subjects: 
Up to a total of 69 evaluable adult subjects who are naive to anti-PD1/PDL1 therapy will be enroled in the 
study. 
 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 13 of 99 
For Cohort A: Up to 26 subjects who have CRC with nonresectable liver metastases suitable for IT injection 
and who have received at least 2 prior standard of care systemic anticancer therapies for 
advanced/metastatic disease will be enroled. Subjects who have had resection of hepatic metastases and 
have hepatic recurrence, need to have had only 1 or more prior standard of care systemic anticancer 
therapies in order to be eligible for this study. Initially, 11 subjects will be enroled and data reviewed by a 
DMC to recommend on extending the cohort with an additional 15 subjects. Note that for the efficacy 
analysis, the required number of subjects refers to those with MSS (pMMR) disease. This will be 
determined during the study and therefore subjects with MSI-H (dMMR) disease will be replaced. Given 
the low incidence of MSI in stage IV CRC, it is expected that this number will be low, ie, approximately 
1 to 2 subjects to be replaced. Subjects with MSI disease will be included in the safety analysis set. 
 
For Cohort B: Up to 43 subjects who have GC/GEJ cancer with nonresectable liver metastases suitable for 
IT injection and who have received at least 1 prior standard of care systemic anticancer therapy for 
advanced/metastatic disease will be eligible for this study. Initially, 18 subjects will be enroled and data 
reviewed by a DMC to recommend on extending the cohort with an additional 25 subjects. Note that for 
the efficacy analysis, the required number of subjects refers to those with MSS (pMMR) disease. This will 
be determined during the study and therefore subjects with MSI-H (dMMR) disease will be replaced. Given 
the low incidence of MSI in GC/GEJ, it is expected that this number will be low, ie, approximately 
1 to 2 subjects to be replaced. Subjects with MSI disease will be included in the safety analysis set. 
 
Treatment Groups and Duration: 
Study treatment will consist of BO-112 IT injections in combination with intravenous (IV) pembrolizumab 
infusions and will be administered in 3-week cycles. For each cycle, BO-112 IT injections will be 
administered after the pembrolizumab infusion, either the same day or within a period of up to 36 hours 
after the pembrolizumab infusion (for organisational feasibility at the site). 
The overall study duration is highly dependent on the duration of achieved clinical benefit, and thus 
expected to be in the range of 24 to 36 months. 
Individual subject study duration will depend on maintenance of clinical benefit and tolerability and is 
expected to range from 2 to 12 months 
 
Statistical Methods: 
Approximately 80 subjects will be screened to achieve a total of 69 evaluable subjects. 
The sample sizes of the cohorts were determined using Simon’s 2-stage design to enable a first evaluation 
of the treatment’s activity on tumour response. The designs are based on a 1-sided  = 0.05; a power 80% 
and response probabilities based on RECIST 1.1 noted below. 
 
• 
Cohort A (CRC): response probability based on RECIST 1.1 of P0 = 1% to be tested against the 
alternative (desirable) response probability of P1 = 15%. For the first stage, 11 subjects* (N1) will 
be enroled and if no responses are observed, the study may be stopped for futility. If 1 or more 
responses are observed, an additional 15 subjects* (N2) will be enroled for a total of N = 26 
subjects.  
* The baseline biopsy sample will be evaluated for proficient mismatch repair (pMMR, as proxy 
of MSS) vs. deficient mismatch repair (dMMR, as proxy of MSI-H) status in Cohort A and subjects 
who are dMMR will be replaced to ensure the appropriate number of MSS/pMMR subjects for the 
statistical analysis. Data from subjects with dMMR CRC will be evaluated as part of the safety 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 14 of 99 
population for safety parameters, but separately and descriptively for efficacy endpoints. 
 
• 
Cohort B (GC): response probability based on RECIST 1.1 of P0 = 10% to be tested against the 
alternative (desirable) response probability P1 = 25%. For the first stage, 18 subjects** (N1) will be 
enroled and if 2 or less responses are observed, the study may be stopped for futility. If 3 or more 
responses are observed, an additional 25 subjects** (N2) will be enroled for a total of N = 43 
subjects.  
** The baseline biopsy sample will be evaluated for pMMR (as proxy of MSS) vs. dMMR  (as 
proxy of MSI-H) status in Cohort B and subjects who are MSI-H/dMMR will be replaced to ensure 
the appropriate number of pMMR subjects for the statistical analysis. Data from subjects with 
dMMR GC/GEJ will be evaluated as part of the safety population for safety parameters, but 
separately and descriptively for efficacy endpoints. 
 
Data Monitoring Committee: 
When the prespecified number of subjects for Stage 1 have been enroled and have reached at least the first 
on-study response assessment, a DMC will review the safety and efficacy data per cohort. Enrolment will 
be suspended per cohort and the DMC will review the safety and efficacy data available at the time that the 
last subject enrolled has reached the first on-study response assessment at Week 7 (= Cycle 3). The DMC 
will make a recommendation to the Sponsor separately for each cohort regarding expanding to the total 
foreseen sample size. 
 
1.2 
Schema 
Figure 1 
Study Schema 
Abbreviations: CRC=colorectal cancer; GC/GEJ= gastric or gastro-oesophageal junction cancer. Note: for Cohort A 
that number refers to microsatellite stable (MSS) subjects, and actual number may be somewhat higher due to 
replacement of microsatellite instable (MSI) subjects. 
 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 15 of 99 
1.3 
Schedule of Activities 
Table 1 
Schedule of Assessments 
Treatment Cycle  
  
1  
2  
3  
4  
5  
6, 8 … 34  
7, 9 … 35  
EOS  
Visit  
Screening  
V1a  
Baseline 
V1b  
V2  
V3  
V4  
V5  
V6, V8 ...  
V34  
(even 
numbered 
visits)  
V7, V9 …  
V35 (odd 
numbered 
visits)  
  
EOS   
Day of visit within 
treatment cycle  
Day -28 to 
Day -1  
Day 1  
  
Day 8       
  2 days  
Day 1  
 2 days  
Day 1  
 2 days  
Day 1   
 2 days  
Day 1  
 2 days  
Days 1 
 2 days  
Days 1  
 2 days  
28 days after 
last  
treatment  
  3 days   
Study Week  
  
W1  
W2  
W4  
W7  
W10  
W13  
W16, W22 … 
W100  
W19, W25 … 
W103  
  
Administrative procedures  
Informed consent Form  
X  
  
  
  
  
  
  
  
  
  
Inclusion/Exclusion 
criteria  
X  
  
  
  
  
  
  
  
  
  
Demography  
X  
  
  
  
  
  
  
  
  
  
Medical history   
X  
  
  
  
  
  
  
  
  
  
Safety  
Physical examinationa  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
Vital signsa  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
12-Lead ECG  
X  
X  
  
  
  
  
X  
  
X  
  
ECOG PSa   
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
Adverse eventsa   
  
X  
X  
X  
X  
X  
X  
X  
X  
X  
Concomitant 
medicationa  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
Coagulation b   
X  
X  
X  
X  
X  
X  
X  
X  
X  
  

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 16 of 99 
Treatment Cycle  
  
1  
2  
3  
4  
5  
6, 8 … 34  
7, 9 … 35  
EOS  
Visit  
Screening  
V1a  
Baseline 
V1b  
V2  
V3  
V4  
V5  
V6, V8 ...  
V34  
(even 
numbered 
visits)  
V7, V9 …  
V35 (odd 
numbered 
visits)  
  
EOS   
Day of visit within 
treatment cycle  
Day -28 to 
Day -1  
Day 1  
  
Day 8  
 2 days  
Day 1  
 2 days  
Day 1  
 2 days  
Day 1 
  2 days  
Day 1  
 2 days  
Days 1  
 2 days  
Days 1 
 2 days  
28 days after 
last  
treatment  
  3 days   
Study Week  
  
W1  
W2  
W4  
W7  
W10  
W13  
W16, W22 … 
W100  
W19, W25 … 
W103  
  
Haematologyb, c  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
Chemistry, CRPb, d  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
Thyroid function testse  
  
X  
  
  
X  
  
X  
 
X  
X  
Pregnancy (for WOBCP 
only)f  
X  
  
  
  
X  
  
X  
  
X  
X  
Efficacy  
Tumour Biopsyg  
  
X  
  
X  
  
  
  
  
  
  
Tumour burden and 
response assessment 
(per RECIST 1.1)h,i  
X  
  
  
  
X  
  
X  
V7 and V9  then V12, 
V15, V18, V21,  
V24, V27, V30, V33  
  
Pharmacokinetics  
PK blood samplej  
  
X  
  
  
  
  
  
  
  
  
Study drug administration  
  
  
  
  
  
  
  
  
Pembrolizumab  
Xk  
  
X  
X  
X  
X  
X  
X  
  
BO-112l   
X  
X  
X  
X  
X  
X  
X  
X  
  
Abbreviations: AE=adverse events; CRP= C-reactive protein; CT= computed tomography; ECG=electrocardiogram; ECOG PS= Eastern Cooperative Oncology  
Group Performance Status; EOS=End of Study; PK=Pharmacokinetic; RECIST= response evaluation criteria in solid tumours; SAE=serious adverse events;  
V=visit; WOCBP=woman of childbearing potential  

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 17 of 99 
Notes:  
a. 
Physical examination (full examination at baseline, and brief examination subsequently), ECOG PS, AE recording and concomitant medications recordings will be evaluated 
every 3 weeks (Q3W) prior to pembrolizumab treatment and prior to BO-112 injection at Week 2. Physical examination will include measurement of body weight. Also, vital 
signs will be collected on the same visits and temperature, pulse rate, and blood pressure, will be assessed.  
b. 
Safety laboratory assessments: standard haematology, chemistry, CRP and coagulation parameters (prothrombin time [PT] and activated partial prothrombin time [aPTT]) 
will be measured prior to pembrolizumab treatment at baseline (V1a), then prior to pembrolizumab treatment at each cycle. Coagulation tests only need to be done if BO-
112 is planned to be administered at that visit. If the safety screening labs are done within 5 days prior to V1a, then these labs do not need to be repeated for V1a, and the 
screening laboratory results for coagulation, haematology and chemistry results will be used for V1a (baseline). Note: safety labs (coagulation, haematology and chemistry) 
need to be done within 2 weeks of start of treatment.   
c. 
Haematology assessment will include white blood cell count with differential, platelet counts, red blood cell (RBC) count, haemoglobin, haematocrit, RBC indices (ie, mean 
corpuscular volume (MCV), mean corpuscular haemoglobin (MCH), % reticulocytes).  
d. 
Clinical chemistry test will include alanine amino transferase (ALT), aspartate amino transferase (AST), alkaline phosphatase, total bilirubin, blood urea nitrogen (BUN), 
creatinine, sodium, potassium, calcium, chloride, magnesium, phosphate, bicarbonate, albumin, total protein, and glucose.  
e. 
Thyroid function (triiodothyronine (T3) or free triiodothyronine (FT3), free thyroxine (FT4) and thyroid stimulating hormone [TSH]) will be measured from blood samples at 
baseline and every 6 weeks.  
f. 
Urine pregnancy test will be performed for all WOCBP. If a urine pregnancy test (within 72 hours prior to treatment) is positive or cannot be confirmed as negative, a serum 
pregnancy test will be required to confirm negative pregnancy.  
g. 
Biopsy will be done at baseline (Week 1) prior to first administration of BO-112, biopsy of the to be injected (injected) lesion and optionally, biopsy of a nonhepatic, not to 
be injected (noninjected) lesion. A post-treatment biopsy of the injected lesion and if applicable noninjected lesion will be done prior to BO-112 administration at Visit 2 
(Week 4). The biopsy should be done at the same intervention as the BO-112 administration. Biopsy samples will also be used for biomarker analysis.  
h. 
The tumour burden assessment as per Response evaluation criteria in solid tumours version 1.1 (RECIST 1.1) using CT scan (or MRI if CT scan is contraindicated) will be done 
at screening (within 4 weeks preceding start of study treatment) and on-study every 6 weeks (ie, on V3 W7, V5 W13, V7 W19, and V9 W25 within a window of  ± 3 days) 
and every 9 weeks after V9 W25 within a window of  ± 7 days.   
i. 
In case of immune unconfirmed progressive disease (iUPD), a confirmatory CT scan should be done between 4 to 6 weeks after the iUPD scan depending on the clinical 
status of the subject and extent of progression (if this interval is 6 weeks after iUPD, this coincides with the next scheduled assessment in the first 24 weeks of the study).  
j. 
Timing of PK samples as follows: “Baseline”: Visit 1a (Cycle 1- Day 1), PK sample taken prior to pembrolizumab administration (which is by definition prior to BO-112). This 
may coincide with the sampling for baseline safety labs. “Post-dose”: Cycle 1, PK sample to be taken 30 to 60 minutes after the first BO-112 administration on Visit 1a (Cycle 1 
– Day 1).  
k. 
Treatment should start within 3 business days of enrolment.  
l. 
The BO-112 IT injections is to be administered after pembrolizumab treatment, within a maximum of 36 hours afterwards (ie, same day or following day of pembrolizumab 
administration).   
 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 18 of 99 
2.0 INTRODUCTION 
Immunotherapy for treating cancer has become an important treatment option for patients with 
advanced, metastatic disease. Treatment benefit was initially established for immune checkpoint 
inhibition of CTLA-4 in melanoma and subsequently more widely for inhibition of the 
programmed cell death protein 1(PD1)/ programmed cell death ligand [PDL]-1 interaction. For the 
latter, this has been established through improved response rates, durable responses and survival 
benefit in a number of cancer types, notably melanoma, non-small cell lung cancer (NSCLC), 
urothelial cancer, squamous cell carcinoma of the head and neck (SCCHN) and renal cell 
carcinoma to name the most common ones. Other cancer types such as colorectal cancer (CRC) 
with microsatellite instability (MSI) or deficient mismatch repair (dMMR) and gastric or gastro-
oesophageal junction (GC/GEJ) cancer have also shown treatment benefit with anti-PD1 
treatment. However, not all patients respond, treatment resistance occurs and some tumour types 
appear inherently refractory to immunotherapy. 
2.1 
Study Rationale 
Checkpoint inhibition provides significant clinical benefit in various types of cancer, with 
blockade of the PD1 receptor and its ligands being the most widely used approach. Some tumours, 
however, evade the immune system and are not, or only poorly responsive to checkpoint inhibition. 
The innate immune system interacts with the adaptive immune system and responds to different 
triggers. The purpose of this study is to evaluate if the combination of activation of the innate 
immune system and blockade of the PD1 immune checkpoint can provide clinical benefit in 
patients with tumours that are poorly or only moderately responsive to monotherapy with an anti-
PD1 agent. Activation of the innate immune system will be via direct intratumoural (IT) 
administration of BO-112. Checkpoint inhibition will be via intravenous infusion of 
pembrolizumab. Metastatic liver lesions have been selected as the site for IT injection for 
2 reasons: to reduce the variability of the microenvironment of the injection site, and to evaluate 
if the TLR3 agonist activity of BO-112 potentially breaks through the generally immune-tolerant 
hepatic microenvironment. 
Indication Selection 
The response rates observed for anti-PD1 therapy in CRC are strikingly different for tumours 
characterised by MSI or dMMR compared with microsatellite stability (MSS) or proficient 
mismatch repair (pMMR). Data from Phase II studies of pembrolizumab and nivolumab in CRC 
demonstrated an objective response rate (ORR) based on Response evaluation criteria in solid 
tumours (RECIST) 1.11 of approximately 32% in case of MSI CRC 2,3 but essentially non-
responsiveness with an ORR of 0% for MSS CRC 4,5. Unfortunately, in advanced/metastatic CRC, 
the proportion of patients with MSI tumours is low and estimated at < 5% 6. Differences in the 
tumour microenvironment (TME) of MSI CRC compared with MSS CRC tumours were 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 19 of 99 
demonstrated in an analysis of surgically resected primary colorectal cancer from 25 patients naive 
to chemotherapy. Although higher levels of tumour-infiltrating lymphocytes and higher expression 
of Th1/Tc1 gene groups (TBX21 and IFNG) and CTL group (CD8A, GZMB, PRF1 and IL21) were 
found in MSI tumours, they are not absent in MSS/pMMR tumours. These differences may be 
predictive of response to anti-PD1 treatment 7. They may also indicate a potential to improve 
treatment outcomes for the MSS tumours, if the relevant changes in gene expression can be 
induced. The target population for efficacy endpoints are subjects with pMMR CRC. This is not 
an eligibility criterium, since MSI/MMR testing is not routine in Europe and requiring this as part 
of the screening procedure would delay the start of treatment. Subjects will have on-study biopsies 
and the MMR status will be evaluated to allow replacement of subjects whose disease is dMMR 
until the required number of MSS (pMMR) subjects for the efficacy analysis is reached. Given 5% 
frequency of dMMR in stage IV CRC, the number of subjects expected to be replaced is very low 
(1 to 2 subjects). Furthermore, MSI-high (MSI-H)/dMMR CRC subjects are expected to have 
better response rates due to pembrolizumab efficacy in this population. As this intended population 
has limited treatment options, including these dMMR CRC subjects is considered acceptable. Data 
from these subjects will contribute to the safety data and will not be used for efficacy analysis. 
Third line and beyond treatment for metastatic CRC provides limited benefit. Regorafenib, an oral 
multikinase inhibitor approved in the third line setting, improved overall survival by 1.5 months 
compared with placebo, but only achieved a median progression-free survival (mPFS) 
improvement of 1 week versus placebo, an ORR based on RECIST 1.1 of 1% versus 0% for 
placebo and disease control rate (DCR) of 41% compared with 15% for placebo 8. More than 50% 
of subjects experienced a Grade 3 or higher drug-related adverse event (AE). 
Gastric and gastro-oesophageal cancer have been shown to have moderate sensitivity to PD1 
inhibition. Pembrolizumab has demonstrated an ORR based on RECIST 1.1 of 11.6% in gastric 
and gastro-oesophageal junction cancer in the third line or beyond setting 9 and has received 
accelerated approval from the FDA for the PD-L1 positive subgroup. Nivolumab has demonstrated 
an ORR of 14% in PDL-1 positive or negative gastric cancer or gastro-oesophageal junction cancer 
(Checkmate 32) and is approved in this indication in Japan. 
There is a high unmet medical need in these indications and combined immunotherapy may be 
able to improve outcomes beyond what monotherapy checkpoint achieves. 
Choice of Lesion for Injection 
In CRC liver metastases, high immune cell density at the invasive tumour margin has been shown 
to be associated with better chemotherapy outcome 10. High immune cell densities, high 
immunoscore and high T and B cell scores were shown to be associated with prolonged survival 
in Stage IV CRC 11. However, the liver is considered an immune privileged organ. In order to deal 
with the many antigens arising from the gut via the portal circulation, the liver must strike a balance 
between tolerating foreign antigens and exhibiting some degree of antimicrobial effect without 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 20 of 99 
inducing liver damage. There are complex interactions which are not fully elucidated but suggest 
that tolerance may be broken through induction of inflammation. TLR3 appears to play a key role 
in that an antiviral response is generated via TLR3-mediated activation of the TRIF pathway 
leading to an inflammatory response, whereas bacterial antigens activate the MyD88 pathway 
which results in a tolerant response 12. Various nonclinical models suggest that inflammation 
induced by viral antigens is mediated through increased number of classical dendritic cells, 
increased levels of IFN and tumour necrosis factor (TNF) as well as decreased number of T-
regulatory cell-inducing plasmacytoid dendritic cells 13. Similarly, a viral infection mimic such as 
polyinosinic-polycytidylic acid (Poly I:C) results in upregulation of genes involved in T-cell 
homing and migration 14. 
These data provide support for the potential of BO-112 injected directly into a liver metastasis to 
generate a tumour-targeted immune response, both locally and systemically via migrating immune 
cells. Potential PD-L1 upregulation by tumour cells or by immune regulatory cells in response to 
BO-112 treatment suggests the need to combine treatment with an anti-PD1 agent such as 
prembrolizumab. 
From a practical perspective, metastatic lesions in the liver are accessible with ultrasound guidance 
for IT injections as well as biopsy. The liver as only site for IT injection is also proposed to reduce 
heterogeneity with regard to the TME. 
2.2 
Background 
BO-112 is noncoding double stranded ribonucleic acid (dsRNA) based on Poly I:C which is 
formulated with polyethyleneimine (PEI). BO-112 is an agonist to toll-like receptor 3 (TLR3) and 
targets the cytosolic helicase melanoma differentiation-associated gene 5 (MDA5) and retinoic 
acid-inducible gene I (RIG-I). By mimicking the effect of a viral infection, it is aimed at mobilising 
the immune system to attack tumour cells. This includes activation of dendritic cells, CD8 T-cell 
infiltration, induction of interferons (IFNs), induction of apoptosis and enhancement of 
immunogenic cell death 15. 
Pembrolizumab is a potent humanised immunoglobulin G4 (IgG4) monoclonal antibody (mAb) 
with high specificity of binding to the PD1receptor, thus inhibiting its interaction with PD-L1 and 
PD-L2. Based on preclinical in vitro data, pembrolizumab has high affinity and potent receptor 
blocking activity for PD1. Pembrolizumab has an acceptable preclinical safety profile and is in 
clinical development as an intravenous (IV) immunotherapy for advanced malignancies. 
Keytruda® (pembrolizumab) is indicated for the treatment of patients across a number of 
indications and has a well-defined and acceptable clinical safety profile. For more details on 
specific indications, refer to the Investigator’s Brochure of pembrolizumab. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 21 of 99 
2.2.1 
Nonclinical Studies 
The importance of intact immune surveillance function in controlling outgrowth of neoplastic 
transformations has been known for decades16. Accumulating evidence shows a correlation 
between tumour-infiltrating lymphocytes in cancer tissue and favourable prognosis in various 
malignancies. In particular, the presence of CD8+ T-cells and the ratio of CD8+ effector 
T-cells/FoxP3+ regulatory T-cells (T-regs) correlates with improved prognosis and long-term 
survival in solid malignancies, such as ovarian, colorectal, and pancreatic cancer; hepatocellular 
carcinoma; malignant melanoma; and renal cell carcinoma. Tumour-infiltrating lymphocytes can 
be expanded ex vivo and reinfused, inducing durable objective tumour responses in cancers such 
as melanoma 17,18. 
The PD-1 receptor-ligand interaction is a major pathway hijacked by tumours to suppress immune 
control. The normal function of PD-1, expressed on the cell surface of activated T-cells under 
healthy conditions, is to down-modulate unwanted or excessive immune responses, including 
autoimmune reactions. PD-1 (encoded by the gene Pdcd1) is an Ig superfamily member related to 
cluster of differentiation 28 (CD28) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) 
that has been shown to negatively regulate antigen receptor signalling upon engagement of its 
ligands (PD L1 and/or PD-L2) 19,20. 
The structure of murine PD-1 has been resolved 21. PD-1 and its family members are type-I 
transmembrane glycoproteins containing an Ig-variable–type domain responsible for ligand 
binding and a cytoplasmic tail responsible for the binding of signaling molecules. The cytoplasmic 
tail of PD-1 contains 2 tyrosine-based signaling motifs, an immunoreceptor tyrosine-based 
inhibition motif, and an immunoreceptor tyrosine-based switch motif. Following T-cell 
stimulation, PD-1 recruits the tyrosine phosphatases, SHP-1 and SHP-2, to the immunoreceptor 
tyrosine-based switch motif within its cytoplasmic tail, leading to the dephosphorylation of 
effector molecules such as CD3 zeta (CD3ζ), protein kinase C-theta (PKCθ), and zeta-chain-
associated protein kinase (ZAP70), which are involved in the CD3 T-cell signaling cascade 
20,22,23,24. The mechanism by which PD-1 down-modulates T-cell responses is similar to, but 
distinct from, that of CTLA-4, because both molecules regulate an overlapping set of signaling 
proteins 25,26. As a consequence, the PD 1/PD-L1 pathway is an attractive target for therapeutic 
intervention in CRC and GC/GEJ. 
BO-112: 
In vivo mechanism of action studies have shown a complex of mechanisms potentially involved 
in the antitumoural effect of intratumourally administered BO 112 15. The role of the immune 
system appears to be predominant with various immune cells contributing. Conventional type-I 
dendritic cells (cDC1), characterised by the expression of TLR3 in their endosomal compartment 
and their antigen cross-presenting capacity were shown to be a component of the antitumoural 
effect of BO-112. In addition, IFN  activity appears necessary to potentiate the antitumoural 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 22 of 99 
activity. This was demonstrated in tumour growth models using IFN alpha receptor (IFNAR) 
knockout mice. Further, in vivo experiments highlighted the role of tumour-specific CD8 T-cells 
in halting both local (injected) tumour and distant tumour progression. Some additive effects of 
combining IT BO-112 with systemic anti-PDL1 inhibition have also been observed and tumour 
specificity of the T-cells was demonstrated using tumour-specific epitope staining. 
To investigate whether CD8, CD4 T-cells or IFN are involved in the BO-112 antitumour mediated 
effect, T-cell and IFN depletion experiments were performed in colon cancer and melanoma 
syngeneic tumour models. Tumour growth suppression remained in case of CD4 T-cell depletion 
but was lost upon cessation of BO-112 treatment in case of CD8 T-cell depletion, indicating the 
requirement of CD8 T-cells for maintenance of the achieved antitumoural effect, but not for the 
initial antitumoural effect. This was further verified by neutralising IFN in the model, as this is a 
cytokine secreted by CD8 Tcells. Administration of anti-IFN antibodies resulted in loss of the 
tumour suppressive effect of BO-112. More details on nonclinicial data for BO-112 can be found 
in the BO-112 Investigator’s Brochure. 
Pembrolizumab: 
Therapeutic studies in mouse models have shown that administration of antibodies blocking PD-
1/PD-L1 interaction enhances infiltration of tumour-specific CD8+ T-cells and ultimately leads to 
tumour rejection, either as a monotherapy or in combination with other treatment modalities 27,28, 
29,30,31,32,33. Anti-mouse PD-1 or anti-mouse PD-L1 antibodies have demonstrated antitumour 
responses in models of squamous cell carcinoma, pancreatic carcinoma, melanoma, acute myeloid 
leukaemia and colorectal carcinoma 30,32,33,34,21. In such studies, tumour infiltration by CD8+ 
T-cells and increased IFN-γ, granzyme B and perforin expression were observed, indicating that 
the mechanism underlying the antitumour activity of PD-1 checkpoint inhibition involved local 
infiltration and activation of effector T-cell function in vivo 32. Experiments have confirmed the in 
vivo efficacy of anti-mouse PD-1 antibody as a monotherapy, as well as in combination with 
chemotherapy, in syngeneic mouse tumour models (see the pembrolizumab Investigator’s 
Brochure). 
2.2.2 
Clinical Studies 
BO-112: Clinical data are available for BO-112 from single agent Part 1 (N = 16) and from 
combination treatment Part 2 (N = 28) of a Phase I clinical study (Protocol 112/2016-02, 
NCT02828098). This study evaluated single agent BO-112 at a dose of 0.6 and 1 mg IT injections, 
and at a dose of 1 mg IT injections in combination with IV administered pembrolizumab or 
nivolumab. 
Tumour biopsy results from the single agent Part 1 showed increased expression of gene signatures 
for IFN, IFN, CD8 T-cell activation, CTL effector function and tumour inflammation at both 
doses evaluated. These subjects had advanced, metastatic solid tumours including melanoma, 
leiomyosarcoma, breast cancer and others (1 subject had CRC), with metastatic lesions suitable 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 23 of 99 
for IT injection at various sites, mainly lymph nodes and (sub)cutaneous lesions 35,36. Two subjects 
in Part 1 had a liver lesion as the site of injection. Neither reported any AEs directly associated 
with the injection procedure. Mild flu-like symptoms were reported. Alanine aminotransferase 
(ALT), aspartate aminotransferase (AST) and total bilirubin values remained in the normal range 
for both subjects. Pre- and post- treatment biopsy samples from the injected liver lesions showed 
some antitumoural and immune-related changes. 
Preliminary data from Part 2 in 28 subjects with inherently anti-PD1 refractory tumours (ie, 
determined to be radiologically progressing with no evidence of prior response) show the potential 
of 1 mg intratumourally administered BO-112 in combination with PD1 blockade to sensitise the 
immune system against the tumour with outcomes of disease stabilisation and objective responses 
ORR of 11% (3 subjects achieved partial response [PR], all had increased CD8 T-cells in the on-
treatment tumour biopsy compared to baseline) and DCR of 46%. These subjects had metastatic 
tumour burden from melanoma, NSCLC, SCCHN, or renal cell cancer which was non-responsive 
to the ongoing anti-PD1 treatment and radiologically progressing at study entry. Upon study entry, 
1 mg BO-112 was administered intratumourally to a single lesion (skin/subcutaneous nodule, 
lymph node, soft tissue or visceral metastatic lesion), at intervals varying from 1 to 3 weeks, while 
treatment with pembrolizumab or nivolumab continued as an IV infusion according to the standard 
once every 3 weeks (Q3W) schedule at a dose of 200 mg for pembrolizumab and once every 
2 weeks (Q2W) at a dose of 3 mg/kg or 240mg for nivolumab. 
The safety profile BO-112 (related TEAEs), both as single agent and at the recommended 1 mg 
dose used in combination with anti-PD1 treatment, is currently characterised by generally Grade 1, 
fever (65%) and other flu-like symptoms such as asthenia (32%), chills (21%), myalgia (18%), 
nausea (25%) and vomiting (14%). Injection site pain was reported in 11% of subjects (Grade 1 or 
2). Grade 3 and 4 thrombocytopenia was reported as treatment-related for 2 subjects with 
single-agent BO-112 and Grade 3 pneumonitis was reported as treatment-related in 1 subject in 
the combination Part 2. No decreases in platelet counts have been reported in the combination Part 
2. There were no deaths attributed to study treatment in the Phase 1 study. BO-112 has been 
repeatedly injected in lung (4 subjects in Part 2) and liver (2 subjects in Part 1 and 1 subject in 
Part 2) lesions, all with at least 3 injections at 1-week or longer intervals, in the Phase 1 study. 
These injections were well tolerated. There was only 1 subject with an AE directly related to the 
injection procedure: Grade 1 injection site pain. 
There has been no systemic exposure of BO-112 detected to date after IT administration. 
Further detail of effects of BO-112 in humans can be found in of the Investigator’s Brochure. 
Pembrolizumab: 
Colorectal cancer: The efficacy of pembrolizumab in patients with colorectal cancer that is 
mircosatellite stable (MSS) or mismatch repair proficient (pMMR) is poor, with ORR of 0% 4,5. 
However, in patients with MSI-H or mismatch repair deficient (dMMR) CRC, pembrolizumab 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 24 of 99 
treatment achieved an ORR of 36% (95% CI: 26, 46). The duration of response ranged from 1.6+ 
to 22.7+ months. Data were pooled from 3 studies (KEYNOTE-016, KEYNOTE-028 and 
KEYNOTE-164) which included a total of 90 patients with CRC who were MSI-H or dMMR. 
Patients received either pembrolizumab 200 mg Q3W week or pembrolizumab 10 mg/kg 
Q2W week. A maximum of 24-months treatment with pembrolizumab was administered. A total 
of 84% of patients with metastatic CRC received 2 or more prior lines of therapy. 
Gastric Cancer: The efficacy of pembrolizumab was investigated in KEYNOTE-059 
(NCT02335411), a multicenter, nonrandomised, open-label multi-cohort study that enroled 
259 patients with GC/GEJ adenocarcinoma who progressed on at least 2 prior systemic treatments 
for advanced disease. Among the 259 patients, 55% (n = 143) had tumours that expressed PD-L1 
with a combined positive score of ≥ 1 and MSS tumour status or undetermined MSI or MMR 
status. Patients received pembrolizumab 200 mg Q3W week. Patients without disease progression 
were treated for up to 24 months. For the 143 patients, the ORR was 13.3% (95% CI: 8.2, 20.0); 
1.4% had a complete response (CR) and 11.9% had a PR. Among the 19 responding patients, the 
duration of response ranged from 2.8+ to 19.4+ months, with 11 patients (58%) having responses 
of 6 months or longer and 5 patients (26%) having responses of 12 months or longer. Among the 
259 patients enroled in KEYNOTE-059, 7 (3%) had tumours that were determined to be MSI-H. 
An objective response was observed in 4 patients, including 1 CR. The duration of response ranged 
from 5.3+ to 14.1+ months. 
The safety profile of pembrolizumab as a single agent is characterised by: fatigue, musculoskeletal 
pain, decreased appetite, pruritus, diarrhoea, nausea, rash, pyrexia, cough, dyspnoea, constipation, 
pain and abdominal pain (ie, reported in ≥ 20% of patients). In addition, immune-related AEs 
(irAEs) may occur shortly after the first dose or several months after the last dose of 
pembrolizumab treatment and may affect more than 1 body system simultaneously. Therefore, 
early recognition and initiation of treatment is critical to reduce complications. Based on existing 
clinical study data, most irAEs were reversible and could be managed with interruptions of 
pembrolizumab, administration of corticosteroids and/or other supportive care (for more details 
see Section 1.1 and Table 5. 
2.3 
Benefit/Risk Assessment 
The poor prognosis of patients with unresectable liver metastases for CRC or GC/GEJ who have 
progressed after at least 2 or 1 line of systemic treatment respectively represents a high unmet 
medical need for which investigational agents and/or combination of therapeutic agents may 
provide benefit. In this advanced disease setting, control or reduction of the liver metastases in 
itself may provide a meaningful clinical benefit. Data from a Phase I study of BO-112 added to 
either pembrolizumab or nivolumab in subjects with anti-PD1 refractory tumours, suggest the 
potential of BO-112 to sensitise the immune system against the tumour, including enhanced 
sensitivity to the anti-PD1 treatment, resulting in halting or reversal of the disease progression. 
Safety data from that study indicate that IT injections of BO-112 are well tolerated and have an 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 25 of 99 
acceptable safety profile, also when given in the combination with pembrolizumab. The 
risk/benefit assessment is therefore supportive of further clinical studies. 
 
A specific mention should be done in regards of risk/benefit assessment related to the inclusion 
and management of patients in this trial in the context of COVID-19 pandemic. Our 
recommendations as sponsor have been included in Appendix 9.   
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs of BO-112 and pembrolizumab may be found in the respective Investigator’s 
Brochures. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 26 of 99 
3.0 OBJECTIVES AND ENDPOINTS 
Table 2 
Study Objectives and Endpoints 
Objectives 
Endpoints 
Primary 
 
• Investigation to the anti-tumour 
efficacy and safety of repeated IT 
administrations of BO-112 in 
metastatic liver lesions in 
combination with IV pembrolizumab 
• Efficacy: ORR based on BOR using 
RECIST 1.1 
• Safety: number and proportion of subjects 
with study treatment-related TEAEs with 
severity ≥ Grade 3 (NCI-CTCAE v 5.0) 
Secondary 
 
• Further characterisation of safety 
and of clinical activity of the 
combination as well as determination 
of systemic exposure of BO-112 
• Safety: number and proportion of subjects 
with TEAEs (any grade) 
• Safety: number and proportion of subjects 
with related TEAEs (any grade) 
• Tolerability: number of study 
discontinuations due to related TEAE 
• Efficacy: disease control rate (DCR = CR, 
PR and SD of at least 12 weeks duration) using 
BOR based on RECIST 1.1 
• Efficacy: ORR based on best overall 
response using RECIST modified for immune-
based therapies (iRECIST) 
• Efficacy: DCR = iCR, iPR and iSD of at 
least 12 weeks duration) using iRECIST 
• Efficacy: duration of response 
• Efficacy: progression-free survival 
• Efficacy: overall survival rate at 6 months 
• Pharmacokinetics: systemic exposure after 
first BO-112 administration 
Exploratory 
 
• Evaluation of antitumoural and 
immunological effects in the TME of 
the injected lesion 
• Immune cell profile of TME in injected 
and noninjected lesions 
• Genetic  analysis of the TME 
 
 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 27 of 99 
4.0 STUDY DESIGN 
4.1 
Overall Design 
The purpose of this Phase II study is to evaluate the safety, tolerability, antitumoural activity and 
systemic exposure of repeated IT administrations of BO-112, percutaneously injected into a 
hepatic metastatic lesion in combination with IV administered pembrolizumab. 
This is an open-label, non-comparative, 2-cohort study with a Simon’s 2-stage design and will 
include up to 69 evaluable adult subjects with CRC (MSS) or GC/GEJ who are naive to 
anti-PD1/PDL1 therapy. Cohort A will consist of up to 26 subjects with CRC (MSS) with 
nonresectable liver metastases suitable for IT injection and who have received at least 2 prior 
standard of care systemic anticancer therapies for advanced/metastatic disease. Subjects who have 
had resection of hepatic metastases and have hepatic recurrence, need to have had only 1 or more 
prior standard of care systemic anticancer therapies in order to be eligible for this study. Note that 
for the efficacy analysis, the required number of subjects refers to those with pMMR disease. This 
will be determined during the study and therefore subjects with dMMR disease will be replaced. 
Given the low incidence of dMMR in stage IV CRC, it is expected that this number will be low, 
ie, approximately 1 to 2 subjects to be replaced. Subjects with dMMR disease will be included in 
the safety analysis set. 
Cohort B will consist of up to 43 subjects with gastric or GC/GEJ with nonresectable liver 
metastases suitable for IT injection and who have received at least 1 prior standard of care systemic 
anticancer therapy for advanced/metastatic disease. Note that for the efficacy analysis, the required 
number of subjects refers to those with pMMR disease. This will be determined during the study 
and therefore subjects with dMMR disease will be replaced. Given the low incidence of dMMR in 
GC/GEJ, it is expected that this number will be low, ie, approximately 1 to 2 subjects to be 
replaced. Subjects with dMMR disease will be included in the safety analysis set. See Section 1.2 
for study Schema. 
The overall duration of the study until completion of data analysis is highly dependent on the 
duration of achieved clinical benefit, and therefore expected to be between 24 and 36 months. 
Screening 
The screening period will be from Days -28 to -1, ie, within 4 weeks before the start of the 
treatment. The screening assessments will be performed according to the Schedule of Assessments 
(SoA; see Section 1.3). Baseline will be at Week 1. 
Study Treatment Period 
The study treatment period will comprise 3-week cycles. Treatment and assessment schedules vary 
somewhat over time and are described in detail in Section 6.0 and section 1.3, respectively. The 
overall study duration could be extended up to 2 years (ie, Visit 35 plus the end of study [EOS] 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 28 of 99 
visit 28 days after last dose of treatment) depending on the achieved clinical benefit. Individual 
subject study duration will depend on maintenance of clinical benefit and tolerability and is 
expected to range from 2 to 12 months, although the study foresees 2 years of treatment. 
The study treatment will consist of BO-112 IT injections in combination with IV infusion of 
pembrolizumab infusions and will be administered in 3-week cycles for both Cohort A and 
Cohort B subjects. 
BO-112 (1 mg) and pembrolizumab (200 mg) will be administered as described in Section 6.1. 
Blood samples will be collected for haematology, renal function and hepatic functions tests, 
C-reactive protein (CRP), and coagulation parameters measurements, prior to any study drug 
administration at any visit for the first 13 weeks and subsequently every 6 weeks. 
Urine pregnancy test will be performed for all women of childbearing potential (WOCBP). If a 
urine pregnancy test (within 72 hours prior to treatment) is positive or cannot be confirmed as 
negative, a serum pregnancy test will be required to confirm negative pregnancy.  
Tumour biopsies will be performed at baseline (Week 1) prior to first administration of BO-112, 
on the “to be injected (injected)” lesions and optionally, of a non-hepatic “not to be injected 
(noninjected)” lesion. On the Week 4, 1 post-treatment biopsy of the injected lesion and if 
applicable, of the noninjected lesion will be performed. 
Physical examinations (full at baseline and brief at subsequent visits), Eastern Oncology 
Cooperative Group (ECOG) performance status37, AEs, concomitant medications will be 
evaluated at screening and each visit (ie, at Week 1, Week 2, and Q3W week thereafter) prior to 
the pembrolizumab treatment. 
End of Study 
An EOS visit will be performed for all subjects at 4 weeks after last administered study treatment. 
4.2 
Scientific Rationale for Study Design 
Treatment with pembrolizumab has led to long term durable responses in patients with dMMR 
CRC (estimate of progression-free survival [PFS] at 1 year is 76%4 ) and with MSI and PD-L1 
positive gastric or gastro-oesophageal junction cancer (median duration of response 8.4 months9). 
However, patients with pMMR CRC have not achieved objective responses with pembrolizumab 
and only around 12% of GC/GEJ patients have achieved an objective response. Clinical activity 
of BO-112 in anti-PD1 refractory patients suggests that combining BO-112 with pembrolizumab 
may provide clinical benefit in non- or poorly responsive tumour types such as dMMR CRC and 
GC/GEJ. To limit the number of subjects exposed to a potentially non-effective treatment, a 
Simon’s 2-stage design has been applied with a DMC review of available safety and efficacy data 
of the Stage 1 subjects for each cohort separately. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 29 of 99 
4.3 
Justification for Dose 
BO-112 is a suspension for injection, intended only for IT injection and has a concentration of 
0.6 mg/mL. The recommended dose for BO-112 is 1 mg administered in 1.7 mL volume as an IT 
injection. This dose was shown to have single agent biological activity and to have both biological 
and clinical activity when given in combination with pembrolizumab or nivolumab in a Phase I 
study of subjects with advanced/metastatic solid tumours (see Section 2.2). 
The planned dose of pembrolizumab for this study is 200 mg Q3W. Based on the totality of data 
generated in the Keytruda development programme, 200 mg Q3W is the appropriate dose of 
pembrolizumab for adults across all indications and regardless of tumour type. As outlined below, 
this dose is justified by: 
• Clinical data from 8 randomised studies demonstrating flat dose- and exposure-efficacy 
relationships from 2 mg/kg Q3W to 10 mg/kg Q2W,  
• Clinical data showing meaningful improvement in benefit-risk including overall survival at 
200 mg Q3W across multiple indications, and 
• Pharmacology data showing full target saturation in both systemic circulation (inferred from 
pharmacokinetic [PK] data) and tumour (inferred from physiologically-based PK [PBPK] 
analysis) at 200 mg Q3W. 
Among the 8 randomised dose-comparison studies, a total of 2262 subjects were enroled with 
melanoma and NSCLC, covering different disease settings (treatment naive, previously treated, 
PD-L1 enriched, and all-comers) and different treatment settings (monotherapy and in 
combination with chemotherapy). Five studies compared 2 mg/kg Q3W versus 10 mg/kg Q2W 
(KN001 Cohort B2, KN001 Cohort D, KN002, KN010 and KN021), and 3 studies compared 10 
mg/kg Q3W versus 10 mg/kg Q2W (KN001 Cohort B3, KN001 Cohort F2 and KN006). All these 
studies demonstrated flat dose- and exposure-response relationships across the doses studied 
representing an approximate 5- to 7.5 folds difference in exposure. The 2 mg/kg (or 200 mg fixed-
dose) Q3W provided similar responses to the highest doses studied. Subsequently, flat dose-
exposure-response relationships were also observed in other tumour types including head and neck 
cancer, bladder cancer, gastric cancer and classical Hodgkin Lymphoma, confirming 200 mg Q3W 
as the appropriate dose independent of the tumour type. These findings are consistent with the 
mechanism of action of pembrolizumab, which acts by interaction with immune cells, and not via 
direct binding to cancer cells. 
Additionally, pharmacology data clearly show target saturation at 200 mg Q3W. First, PK data in 
KN001 evaluating target-mediated drug disposition conclusively demonstrated saturation of PD-1 
in systemic circulation at doses much lower than 200 mg Q3W. Second, a PBPK analysis was 
conducted to predict tumour PD-1 saturation over a wide range of tumour penetration and PD-1 
expression. This evaluation concluded that pembrolizumab at 200 mg Q3W achieves full PD-1 
saturation in both blood and tumour. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 30 of 99 
Finally, population PK analysis of pembrolizumab, which characterised the influence of body 
weight and other subject covariates on exposure, has shown that the fixed-dosing provides similar 
control of PK variability as weight-based dosing, with considerable overlap in the distribution of 
exposures from the 200 mg Q3W fixed-dose and 2 mg/kg Q3W dose. Supported by these PK 
characteristics and given that fixed-dose has advantages of reduced dosing complexity and reduced 
potential of dosing errors, the 200 mg Q3W fixed-dose was selected for evaluation across many 
pembrolizumab protocols. 
4.4 
End of Study Definition 
A subject is considered to have completed the study if he/she has 
• Completed the full 35 cycles of treatment 
or 
• Discontinued treatment and study due to confirmed disease progression and has completed 
the EOS visit. 
Therefore, subjects are not considered to have completed if any of the following apply: 
• Withdrawal due to AE 
• Withdrawal of consent (patient decision to stop) 
• Unconfirmed PD 
• Lost to follow-up 
• Any other reason 
The end of the study is defined as the date of the last visit of the last subject in the study or last 
scheduled procedure shown in the SoA for the last subject in the study globally. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 31 of 99 
5.0 STUDY POPULATION 
Prospective approval of protocol deviations to recruitment and enrolment criteria, also known as 
protocol waivers or exemptions, is in general not permitted. Minor deviations from timing and 
some laboratory parameters may be discussed with the Sponsor in exceptional cases. 
5.1 
Inclusion Criteria 
Subjects will be included in the study only if all the following inclusion criteria are met: 
1. Be willing and able to give written informed consent for the study. 
2. Be  18 years of age on day of signing informed consent. 
3. Have nonresectable liver metastasis(es) of colorectal or GC/GEJ cancer. History of resection 
for liver metastasis is allowed. 
4. Have histological or cytological proof of colorectal (Cohort A) or GC/GEJ cancer (Cohort B). 
5. Have progressed during or after, or have not tolerated therapy for advanced/metastatic disease 
as follows: 
a. Cohort A (CRC): at least 2 lines of fluoropyrimidine, irinotecan and/or oxaliplatin 
containing therapy with or without bevacizumab according to institutional practice; if 
epidermal growth factor receptor (EGFR) positive/RAS wild type, prior anti-EGFR 
treatment is required. In case of prior resection of hepatic metastasis with hepatic 
recurrence, only 1 prior line of fluoropyrimidine, irinotecan and/or oxaliplatin containing 
therapy is required. 
b. Cohort B (GC/GEJ): fluoropyrimidine and platinum containing treatment; if HER-2 
positive, also prior anti-HER-2 treatment is required. 
6. Have at least 1 liver metastasis of minimum 20 mm in diameter that is suitable for 
percutaneous, IT injection (including, but not limited to absence of tumour infiltration into the 
main portal vein, hepatic vein or vena cava). Recurrence in liver of previously resected liver 
metastasis is allowed. 
7. Presence of at least 1 measurable lesion according to RECIST v1.1. Note: this may be the liver 
metastasis selected for injection if it is the only measurable lesion present. 
8. ECOG performance status of 0 or 1 (see Appendix 8). 
9. Adequate haematologic and end-organ function defined by the following laboratory results 
obtained within 2 weeks prior to the first dose of study treatment: 
a. ANC ≥ 1.5 × 109/L 
b. Platelet count ≥ 100 × 109/L 
c. Haemoglobin ≥ 9.0 g/dL 
d. AST and ALT  5 × upper limit of normal (ULN) 
e. Serum total bilirubin  2 × ULN (if known Gilbert’s syndrome, serum bilirubin level  3 × 
ULN) 
f. Prothrombin time (PT) (or international normalised ratio [INR]) within normal limits and 
activated partial prothrombin time (aPTT) within normal limits 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 32 of 99 
g. Serum albumin ≥ 2.5 g/dL 
h. Serum creatinine  1.5 × ULN or creatinine clearance ≥ 30 mL/min (calculated per 
Cockroft-Gault formula ) 
10. Female subjects who are not pregnant or breastfeeding and at least 1 of the following 
conditions applies:  
a) Not a WOCBP  
b) WOCBP who agrees to follow contraception guidance during the treatment period and for 
at least 120 days after the last dose of study treatment. 
11. Able and willing to comply with study and follow-up procedures. 
5.2 
Exclusion Criteria 
Subjects are excluded from the study if any of the following criteria apply: 
1. Prior treatment with an anti-PD1, anti-PDL1 or anti-PDL2 agent, an agent directed to another 
stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX40, CD137) or any Toll-like 
receptor (TLR) agonist. 
2. Liver metastasis(es) with macroscopic tumour infiltration into the main portal vein, hepatic 
vein or vena cava. 
3. Contraindications to tumour biopsy and injections of the hepatic metastasis(es), such as 
coagulopathy, therapeutic dose anticoagulant treatment and treatment with long-acting agents 
such as clopidogrel which cannot be safely stopped. 
4. Chemotherapy, definitive (curative) radiation, or biological cancer therapy within 4 weeks 
prior to the first dose of study treatment. Note: Participants must have recovered from all AEs 
due to previous therapies to ≤ Grade 1 or baseline. Participants with ≤ Grade 2 neuropathy may 
be eligible. 
5. Palliative radiotherapy (≤ 2 weeks of radiotherapy) within 1 week of start of study treatment. 
Subjects must have recovered from all radiation-related toxicities, not require corticosteroids, 
and not have had radiation pneumonitis. 
6. Clinically active central nervous system (CNS) metastases and/or carcinomatosis meningitis. 
Subjects with previously treated brain metastases may participate provided they are 
radiologically stable, ie, without evidence of progression for at least 4 weeks by repeat imaging 
(note that the repeat imaging should be performed during study screening), clinically stable 
and without requirement of steroid treatment for at least 14 days prior to first dose of study 
treatment. 
7. History of a second malignancy, unless potentially curative treatment has been completed with 
no evidence of malignancy for 2 years. 
8. Life expectancy of < 12 weeks. 
9. Severe hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipients. 
10. Active infection requiring systemic therapy. 
11. History of (non-infectious) pneumonitis that required steroids or current pneumonitis. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 33 of 99 
12. Active autoimmune disease that required systemic treatment in past 2 years (ie, with use of 
disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy 
(eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or 
pituitary insufficiency) is not considered a form of systemic treatment and is allowed. 
13. Receiving systemic immunosuppressive therapy within 28 days before enrolment with the 
exceptions of intranasal, topical, and inhaled corticosteroids or oral corticosteroids at 
physiological doses not to exceed 10 mg/day of prednisone or equivalent. 
14. Known human immunodeficiency virus (HIV) infection. 
15. Known history of hepatitis B (defined as HbsAg reactive) or known active hepatitis C (defined 
as HCV RNA [qualitative] detected) virus infection. 
16. For WOCBP: pregnancy or a positive urine pregnancy test (eg within 72 hours) prior to 
treatment; or breastfeeding. If the urine test is positive or cannot be confirmed as negative, a 
serum pregnancy test will be required. 
17. Any other medical condition which would impact the safety of the subject or interfere with the 
subject’s ability to comply with the study and follow-up procedures, in the opinion of the 
investigator. 
18. Has received a live vaccine within 28 days prior to the first dose of study drug. Examples of 
live vaccines include, but are not limited to, the following: measles, mumps, rubella, 
varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette–Guérin (BCG), and 
typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines 
and are allowed; however, intranasal influenza vaccines are live attenuated vaccines and are 
not allowed. 
19. Is currently participating or has participated in a study of an investigational agent or has used 
an investigational device within 4 weeks prior to the first dose of study treatment, (subjects 
who are in a follow-up phase of an investigational study may participate as long as it has been 
4 weeks after the last dose of the previous investigational agent). 
20. Has had an allogenic tissue/solid organ transplant. 
 
5.3 
Lifestyle Considerations 
Meals and Dietary Restrictions 
Study subjects should maintain a normal diet unless modifications are required to manage an AE 
such as diarrhoea, nausea or vomiting. 
Contraception 
BO-112 and pembrolizumab may have adverse effects on a foetus in utero. Study subjects should 
be informed that taking the study drug may involve unknown risks to the fetus (unborn baby) if 
pregnancy were to occur during the study. In order to participate in the study, subjects of 
childbearing potential must adhere to the contraception requirement from the day of study drug 
initiation (or 14 days prior to the initiation of study drug for oral contraception) throughout the 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 34 of 99 
study period up to 120 days after the last dose of study drug. If there is any question that a study 
subject of childbearing potential will not reliably comply with the requirements for contraception, 
that subject should not be entered into the study. 
Pregnancy 
If a study subject inadvertently becomes pregnant while on treatment with BO-112 or 
pembrolizumab, the subject will be immediately discontinued from study treatment. The site will 
contact the study subject at least monthly and document the subject’s status until the pregnancy 
has been completed or terminated. The outcome of the pregnancy will be reported to the Sponsor 
without delay and within 24 hours if the outcome is a serious adverse event (eg,, death, abortion, 
congenital anomaly, or other disabling or life-threatening complication to the mother or newborn). 
The investigator will make every effort to obtain permission to follow the outcome of the 
pregnancy and report the condition of the foetus or newborn to the Sponsor.  
Use in Nursing Women 
It is unknown whether pembrolizumab is excreted in human milk. Since many drugs are excreted 
in human milk, and because of the potential for serious adverse reactions in the nursing infant, 
subjects who are breastfeeding are not eligible for enrolment. 
5.4 
Screen Failures 
Screen failures are defined as subjects who consent to participate in the clinical study but are not 
subsequently entered in the study. A minimal set of screen failure information is required to ensure 
transparent reporting of screen failure subjects to meet the Consolidated Standards of Reporting 
Trials (CONSORT) publishing requirements and to respond to queries from regulatory authorities. 
Minimal information includes demography, screen failure details, eligibility criteria, and any 
serious adverse event (SAE). 
Individuals who do not meet the criteria for participation in this study (screen failure) may or may 
not be rescreened depending on the reasons for screen failure. Rescreened subjects should not be 
assigned the same subject number as for the initial screening. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 35 of 99 
6.0 STUDY TREATMENT 
Study treatment is defined as any investigational treatment(s) or marketed product(s) intended to 
be administered to a subject according to the study protocol. 
6.1 
Study Treatment(s) Administered 
The recommended dose for further clinical development of BO-112 is 1 mg administered in 1.7 mL 
volume. The planned dose of pembrolizumab for this study is 200 mg (See Table 4). Study 
treatment will consist of BO-112 IT injections in combination with IV pembrolizumab infusions 
and will be administered in 3-week cycles. For each cycle, BO-112 IT injections will be 
administered after the pembrolizumab infusion, either the same day or within a period of up to 36 
hours after the pembrolizumab infusion (for organisational feasibility at the site). 
BO-112 IT Injections 
The BO-112 IT injections will be administered by an interventional radiologist under ultrasound 
guidance, or occasional CT scan guidance at the discretion of the interventional radiologist. 
Preparatory and post-procedural measures such as those routinely used in institutional practice 
regarding sterility measures and local anaesthetic use for percutaneous biopsy of the liver will be 
applied for each IT injection. There are no specifications regarding needle size or length as this 
will be dependent on the depth of the lesion to be injected and will be determined at the discretion 
of the interventional radiologist. The lesion should be punctured once and the volume to be injected 
should be distributed to the extent possible within the lesion either via deep penetration of the 
lesion and injection as the needle is withdrawn through the lesion, or via small volume injections 
at different points within the lesion in a ‘fan-like’ fashion without full removal of the needle from 
the lesion. Caution must be used to avoid injection of BO-112 outside of the intended lesion. 
• Cycle 1: BO-112 1 mg in 1.7 mL volume will be percutaneously injected intratumourally in 
the liver lesion on Days 1 or 2 (V1a, W1) up to 36 hours after pembrolizumab infusion and on 
Day 8 (V1b, W2). 
• Cycle 2 and all further cycles: BO-112 1 mg in 1.7 mL volume will be percutaneously injected 
intratumourally in the liver lesion(s) on the first or second day of each 3-week cycle, up to 36 
hours after pembrolizumab infusion. 
o If there is more than 1 injectable liver lesion, the injected lesion may be alternated 
across cycles. 
o If the previously injected liver lesion becomes too small to inject the full volume, the 
volume may be divided across other liver lesions if present, to ensure the total IT 
administered dose of 1 mg. 
o If the full dose (volume) cannot be safely administered to 1 or more liver lesions, then 
that dose should be omitted. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 36 of 99 
Pembrolizumab Intravenous Infusions 
For all cycles: pembrolizumab will be administered using IV infusion on Day 1 of each 
3-week treatment cycle prior to the BO-112 IT injection, starting in Visit 1a Week 1. 
Pembrolizumab will be administered at a dose of 200 mg using a 30-minute IV infusion. Sites 
should make every effort to target infusion timing to be as close to 30 minutes as possible. 
However, given the variability of infusion pumps from site to site, a window between -5 minutes 
and +10 minutes is permitted (ie, infusion time is 30 minutes (-5 min/+10 min). 
Pembrolizumab may cause severe or life-threatening infusion-reactions including severe 
hypersensitivity or anaphylaxis. Signs and symptoms usually develop during or shortly after drug 
infusion and generally resolve completely within 24 hours of completion of infusion. Dose 
modification and toxicity management guidelines on anti-PD1 associated infusion reaction are 
provided in Table 3. 
Table 3 
Pembrolizumab Infusion Reaction Dose Modification and Treatment 
Guidelines 
NCI-CTCAE Grade 
Treatment 
Premedication at 
Subsequent Dosing 
Grade 1 
Mild reaction; infusion 
interruption not 
indicated; intervention 
not indicated 
• 
Increase monitoring of vital signs as 
medically indicated until the subject is 
deemed medically stable in the opinion of 
the Investigator. 
None 
Grade 2 
Requires therapy or 
infusion interruption 
but responds promptly 
to symptomatic 
treatment (eg, 
antihistamines, 
NSAIDs, narcotics, IV 
fluids); prophylactic 
medications indicated 
for ≤24 hours. 
• 
Stop Infusion. 
• 
Additional appropriate medical therapy may 
include but is not limited to: 
• 
IV fluids 
• 
Antihistamines 
• 
NSAIDs 
• 
Acetaminophen 
• 
Narcotics 
• 
Increase monitoring of vital signs as 
medically indicated until the subject is 
deemed medically stable in the opinion of 
the investigator. 
• 
If symptoms resolve within 1 hour of 
stopping drug infusion, the infusion may be 
restarted at 50% of the original infusion rate 
(eg from 100 to 50 mL/hr.). Otherwise 
dosing will be held until symptoms resolve 
and the subject should be premedicated for 
the next scheduled dose. 
Subjects who develop Grade 2 toxicity despite 
adequate premedication should be permanently 
discontinued from further study drug treatment 
Participant may be 
premedicated 1.5 hours (± 30 
minutes) prior to infusion of 
anti-PD1with: 
Diphenhydramine 50 mg po 
(or equivalent dose of 
antihistamine). 
Acetaminophen 500-1000 mg 
po (or equivalent dose of 
analgesic). 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 37 of 99 
NCI-CTCAE Grade 
Treatment 
Premedication at 
Subsequent Dosing 
Grades 3 or 4 
 
Grade 3: 
Prolonged (ie, not 
rapidly responsive to 
symptomatic 
medication and/or brief 
interruption of 
infusion); recurrence of 
symptoms following 
initial improvement; 
hospitalisation indicated 
for other clinical 
sequelae (eg, renal 
impairment, pulmonary 
infiltrates) 
Grade 4: 
Life-threatening; 
pressor or ventilator 
support indicated 
 
• 
Stop infusion. 
• 
Additional appropriate medical therapy may 
include but is not limited to: 
• 
Epinephrine** 
• 
IV fluids 
• 
Antihistamines 
• 
NSAIDs 
• 
Acetaminophen 
• 
Narcotics 
• 
Oxygen 
• 
Pressors 
• 
Corticosteroids 
• 
Increase monitoring of vital signs as 
medically indicated until the subject is 
deemed medically stable in the opinion of the 
investigator. 
• 
Hospitalisation may be indicated. 
**In cases of anaphylaxis, epinephrine should be 
used immediately. 
Participant is permanently discontinued from 
further study drug treatment. 
 
No subsequent dosing 
Abbreviations: IV=intravenous; NCI-CTCAE=National Cancer Institute-Common Terminology Criteria for Adverse Events; 
NSAID=nonsteroidal anti-inflammatory drug 
Note: Appropriate resuscitation equipment should be available at the bedside and a physician readily available during the period 
of drug administration. For further information, please refer to the Common Terminology Criteria for Adverse Events v4.0 
(CTCAE) at http://ctep.cancer.gov 
 
 
Treatment Scheme 
Abbreviation: W=week; IT=intratumoural; IV=intravenous 
Study treatment should continue as long as there is clinical benefit and it is tolerated, up to a 
maximum of approx. 2 years (corresponding to 35 treatment cycles). In addition, for IT 
administration of BO-112, IT administration continues as long as it is feasible to inject the liver 
lesion(s), including temporary interruptions. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 38 of 99 
Table 4 
Study Treatment Details 
Study Treatment Name: 
 
BO-112 
Anti-PD1 
 
Active ingredient: BO-112 is a 
noncoding dsRNA based on 
polyinosinic-polycytidylic acid (Poly 
I:C), formulated with polyethylenime 
(PEI) 
Active ingredient: 
pembrolizumab (MK-3475) is a 
humanised IgG4mAb 
Dosage Formulation: 
 
Sterile isosmotic suspension. A clear to 
opalescent liquid, with a colourless to 
pale milky aspect and may contain 
functional visible particles 
Solution for infusion. A clear to 
slightly opalescent, colorless to 
slightly yellow solution. 
Unit Dose Strength(s)/Dosage 
Level(s): 
At a dose of 1 mg in 1.7 mL volume 
At a dose of 200 mg using a 
30-minute IV infusion 
Route of Administration  
Intratumoural 
IV infusion 
Dosing Instructions: 
 
For each cycle, BO-112 IT injections 
will be administered after the 
pembrolizumab infusion, either the same 
day or within a period of up to 36 hours 
after the pembrolizumab infusion 
For all cycles: pembrolizumab 
will be administered using IV 
infusion on Day 1 of each 
3-week treatment cycle prior to 
the BO-112 IT injection, starting 
in Visit 1a Week 1 
Packaging and Labelling 
 
BO-112 will be provided in a 12 mL 
glass vial containing 0.6 mg/mL on dry 
basis of active ingredient (Poly I:C) with 
5% (w/v) anhydrous glucose and 
nominal 5.849 mM of PEI, as 
excipients. Each vial will be labelled as 
required per country requirement.  
Pembrolizumab will be provided 
in a 10 mL vial containing 4 mL 
of liquid with 100 mg of 
pembrolizumab. Each vial will 
be labelled as required per 
country requirement. 
Manufacturer 
Highlight Therapeutics S.L. 
Merck Sharpe & Dohme, Corp. 
Abbreviations: IgG4=immunoglobulin G4; IT=intratumoural; IV=intravenous; mAb=monoclonal antibody; PEI= 
polyethyleneimine; Poly I:C= polyinosinic-polycytidylic acid 
 
6.2 
Treatment Continuation Decisions Based on Efficacy 
The decision to continue study treatment will be based on iRECIST guidelines 38. Treatment will 
be discontinued if progressive disease is confirmed (iCPD) within 4 to 6 weeks of immune 
unconfirmed progressive disease (iUPD) or if iUPD is associated with clinical instability, (eg, 
worsening of performance status, need for increased palliative intervention or more intensive 
management of disease-related symptoms). 
6.3 
Dose Modification 
6.3.1 
Dose Modification and Toxicity Management for Immune-related TEAEs 
Treatment-emergent AEs (TEAEs) associated with pembrolizumab exposure may represent an 
immunologic aetiology. These irAEs may occur shortly after the first dose or several months after 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 39 of 99 
the last dose of pembrolizumab treatment and may affect more than 1 body system simultaneously. 
Therefore, early recognition and initiation of treatment is critical to reduce complications. Based 
on existing clinical study data, most irAEs were reversible and could be managed with 
interruptions of pembrolizumab, administration of corticosteroids and/or other supportive care. 
The role of BO-112 in inducing or potentiating the occurrence of anti-PD1 associated irAEs is 
currently unknown and therefore BO-112 treatment must also be interrupted in case of any irAE. 
For suspected irAEs, ensure adequate evaluation to confirm etiology or exclude other causes. 
Additional procedures or tests such as bronchoscopy, endoscopy, and skin biopsy may be included 
as part of the evaluation. Based on the severity of irAEs, withhold or permanently discontinue 
pembrolizumab and BO-112, and administer corticosteroids. Dose modification and toxicity 
management guidelines for irAEs associated with pembrolizumab and/or BO-112 are provided in 
Table 5. 
Individual subject decisions may be discussed with the Sponsor in case of a clinically stable patient 
or one who has clinical benefit which needs to be balanced against the potential risk of continued 
or re-instated study treatment (also see below for additional special cases). 
Table 5 
Dose modification and toxicity management guidelines for irAEs associated 
with pembrolizumab 
General instructions: 
1. Severe and life-threatening irAEs should be treated with IV corticosteroids followed by oral steroids. Other 
immunosuppressive treatment should begin if the irAEs are not controlled by corticosteroids. 
2. Anti-PD1 must be permanently discontinued if the irAE does not resolve or the corticosteroid dose is not 
≤10 mg/day within 12 weeks of the last anti-PD1 treatment. 
3. The corticosteroid taper should begin when the irAE is ≤ Grade 1 and continue at least 4 weeks. 
4. If anti-PD1 has been withheld, anti-PD1 may resume after the irAE decreased to ≤ Grade 1 after corticosteroid 
taper. 
irAEs 
Toxicity grade 
(CTCAE V5.0) 
Action with 
anti-PD1 
Corticosteroid and/or 
other therapies  
Monitoring and follow-up  
Pneumonitis  
Grade 2 
Withhold  
Administer 
corticosteroids 
(initial dose of 
1 - 2 mg/kg 
prednisone or 
equivalent) 
followed by taper 
Add prophylactic 
antibiotics for 
opportunistic 
infections 
 
Monitor subjects for signs 
and symptoms of 
pneumonitis 
Evaluate participants with 
suspected pneumonitis 
with radiographic 
imaging and initiate 
corticosteroid 
treatment 
 
Recurrent 
Grade 2,  
Grade 3 or 4  
Permanently 
discontinue 
Diarrhoea / 
Colitis  
Grade 2 or 3 
Withhold 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 40 of 99 
Recurrent Grade 3 
or Grade 4 
Permanently 
discontinue 
Administer 
corticosteroids 
(initial dose of 
1 - 2 mg/kg 
prednisone or 
equivalent) 
followed by taper 
 
Monitor subjects for signs 
and symptoms of 
enterocolitis (ie, 
diarrhoea, abdominal 
pain, blood or mucus 
in stool with or 
without fever) and of 
bowel perforation (ie, 
peritoneal signs and 
ileus) 
Participants with 
≥ Grade 2 diarrhoea 
suspecting colitis 
should consider GI 
consultation and 
performing endoscopy 
to rule out colitis 
Participants with 
diarrhoea/colitis 
should be advised to 
drink liberal quantities 
of clear fluids. If 
sufficient oral fluid 
intake is not feasible, 
fluid and electrolytes 
should be substituted 
via IV infusion 
AST or ALT 
elevation or 
Increased 
Bilirubin 
Grade 2 a 
Withhold 
Administer 
corticosteroids 
(initial dose of 
0.5 - 1 mg/kg 
prednisone or 
equivalent) 
followed by taper 
Monitor with liver 
function tests 
(consider weekly or 
more frequently until 
liver enzyme value 
returned to baseline or 
is stable) 
Grade 3 b or 4 c 
Permanently 
discontinue 
Administer 
corticosteroids 
(initial dose of 
1 - 2 mg/kg 
prednisone or 
equivalent) 
followed by taper 
Type 1 diabetes 
mellitus (T1DM) 
or Hyperglycemia 
New onset T1DM 
or  
Grade 3 or 4 
hyperglycemia 
associated with 
evidence of -cell 
failure 
Withhold d 
Initiate insulin 
replacement 
therapy for 
subjects with 
T1DM 
Administer anti-
hyperglycemic in 
participants with 
hyperglycemia 
Monitor subjects for 
hyperglycemia or 
other signs and 
symptoms of diabetes 
Hypophysitis 
Grade 2 
Withhold 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 41 of 99 
Grade 3 or 4 
Withhold or 
permanently 
discontinue d 
Administer 
corticosteroids 
and initiate 
hormonal 
replacements as 
clinically 
indicated 
Monitor for signs and 
symptoms of 
hypophysitis 
(including 
hypopituitarism and 
adrenal insufficiency) 
Hyperthyroidism  
Grade 2 
Continue 
Treat with non-
selective beta-
blockers (eg, 
propranolol) or 
thionamides as 
appropriate 
Monitor for signs and 
symptoms of thyroid 
disorders 
Grade 3 or 4 
Withhold or 
permanently 
discontinue d 
Hypothyroidism 
Grade 2, 3, 4 
Continue 
Initiate thyroid 
replacement 
hormones (eg, 
levothyroxine or 
liothyronine) per 
standard of care 
Monitor for signs and 
symptoms of thyroid 
disorders 
Nephritis: 
grading according 
to increased 
creatinine or 
acute kidney 
injury 
Grade 2 
Withhold 
Administer 
corticosteroids 
(prednisone 
1 – 2 mg/kg or 
equivalent) 
followed by taper 
Monitor changes of renal 
function 
Grade 3 or 4 
Permanently 
discontinue 
Myocarditis 
Grade 1 or 2 
Withhold 
Based on severity of 
AE administer 
corticosteroids 
Ensure adequate 
evaluation to confirm 
aetiology and/or 
exclude other causes 
 
Grade 3 or 4 
Permanently 
discontinue 
All Other 
immune-related 
AEs 
Persistent Grade 2 
Withhold 
Based on severity of 
AE administer 
corticosteroids 
Ensure adequate 
evaluation to confirm 
aetiology or exclude 
other causes 
Grade 3 
Withhold or 
discontinue 
based on the 
event e  
Recurrent Grade 3 
or Grade 4  
Permanently 
discontinue 
a AST/ALT: >3.0 - 5.0 x ULN if baseline normal; >3.0 - 5.0 x baseline, if baseline abnormal;  
bilirubin: >1.5 - 3.0 x ULN if baseline normal; >1.5 - 3.0 x baseline if baseline abnormal 
b AST/ALT: > 5.0 to 20.0 x ULN, if baseline normal; >5.0 - 20.0 x baseline, if baseline abnormal;  
bilirubin: >3.0 - 10.0 x ULN if baseline normal; > 3.0 - 10.0 x baseline if baseline abnormal 
c AST/ALT: > 20.0 x ULN, if baseline normal; >20.0 x baseline, if baseline abnormal;  
bilirubin: > 10.0 x ULN if baseline normal; >10.0 x baseline if baseline abnormal 
d The decision to withhold or permanently discontinue anti-PD1 is at the discretion of the investigator or treating 
physician. If control achieved or ≤ Grade 2, anti-PD1 may be resumed. 
e Events that require discontinuation include but are not limited to: Guillain-Barre Syndrome, encephalitis, 
Stevens-Johnson Syndrome and toxic epidermal necrolysis. 
 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 42 of 99 
6.3.2 
Temporary Discontinuation/Interruption 
BO-112: IT administration may be interrupted independently of pembrolizumab treatment (which 
continues as scheduled), in the following situations: 
• Previously injected lesion(s) has decreased to a size for which it is not feasible to administer 
either the full dose, or to divide the full dose across the previously injected lesion and 
another amenable liver lesion, 
• Or the lesion(s) has become non-injectable for other reasons such as density. 
Intratumoural administration of BO-112 should be resumed as soon as feasible at subsequent 
scheduled administrations if the lesions(s) becomes amenable (even if this may be interpreted as a 
sign of progression) and there is no confirmed disease progression. There is no limit on the number 
of such interruptions as long as there is no confirmed disease progression. However, the case 
should be discussed with the Sponsor if 2 or more consecutive BO-112 administrations are omitted. 
Pembrolizumab treatment should continue as scheduled. 
Both BO-112 and pembrolizumab may be interrupted in a subject who is clinically stable and has 
no confirmed disease progression for situations other than those specified in the preceding 
paragraphs. This may include delayed toxicity/diminishing tolerability over time, medical/surgical 
interventions or logistical reasons not related to study treatment. These interruptions should not 
exceed 2 cycles unless discussed with the Sponsor. Subjects should be placed back on study 
treatment within 3 weeks of the scheduled interruption, unless otherwise discussed with the 
Sponsor. The reason for interruption should be documented in the subject’s medical and study 
record. 
6.4 
Preparation/Handling/Storage/Accountability 
BO-112: 
BO-112 drug product is a sterile isosmotic suspension for IT administration, presented in a 12 mL 
glass vial containing 0.6 mg/mL on dry basis of active ingredient (Poly I:C) with 5% (w/v) 
anhydrous glucose and nominal 5.849 mM of PEI, as excipients. It is a clear to opalescent liquid, 
with a colourless to pale milky aspect and may contain functional visible particles. The clear glass 
vials (20R size) are sealed using 20 mm grey bromobutyl stoppers and aluminium caps. 
BO-112 must be stored in the original carton at 2ºC to 8ºC and protected from light. Before being 
administered, vials should be gently mixed a couple of times using a sideways motion for 
homogenisation (avoid stirring, upside down mixing or vigorous mixing). BO-112 must be filtered 
prior to administration (within a time window of 2 hours). The type of filter to be used is a sterile 
and ready-to-use surfactant-free cellulose acetate (polyvinyl chloride-free) filter with 0.8 µm of 
pore size, 28 mm of diameter and 6.2 cm² of filtration area. The filter should have a bidirectional 
use and should be provided in a single blister pack. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 43 of 99 
Current shelf-life is 21 months. This will be updated as stability data accrue. 
Pembrolizumab: 
Pembrolizumab is a solution for IV infusion, presented in a 10 mL clear glass vial containing 4 mL 
of liquid (100 mg drug product). It is a clear to slightly opalescent, colourless to slightly yellow 
solution. 
Pembrolizumab must be stored in the original carton at 2°C to 8°C to protect from light. Do not 
freeze and do not shake the vials. 
After preparation of infusion: from a microbiological point of view, the product, once diluted, 
should be used immediately. The diluted solution must not be frozen. If not used immediately, 
chemical and physical in-use stability of pembrolizumab has been demonstrated for 24 hours at 
2ºC to 8ºC. This 24-hour hold may include up to 6 hours at room temperature (at or below 25°C). 
If refrigerated, the vials and/or IV bags must be allowed to come to room temperature prior to use. 
Accountability: 
1. The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study treatment received and any discrepancies are reported 
and resolved before use of the study treatment. 
2. Only subjects enroled in the study may receive study treatment and only authorised study 
center staff may supply or administer study treatment. All study treatments must be stored in 
a secure, environmentally controlled, and monitored (manual or automated) area in accordance 
with the labelled storage conditions with access limited to the investigator and authorised study 
center staff. 
3. The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study treatment accountability, reconciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposition records). 
4. Further guidance and information for the final disposition of unused study treatment are 
provided in the study Pharmacy Manual. 
The investigator, a member of the study center staff, or a hospital pharmacist must maintain an 
adequate record of the receipt and distribution of all study drugs using the Drug Accountability 
Form. These forms must be available for inspection at any time. 
6.5 
Measures to Minimise Bias: Randomisation and Blinding 
Not applicable as this is an open-label study. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 44 of 99 
6.6 
Study Treatment Compliance 
The prescribed dosage, timing and mode of administration may not be changed, except as defined 
in Section 1.1. Any departures from the intended regimen must be recorded in the electronic case 
report forms (eCRFs). 
6.7 
Concomitant Therapy 
Any medication or vaccine (including over-the-counter or prescription medicines, vitamins, and/or 
herbal supplements) that the subject is receiving at the time of enrolment (within 28 days before 
the time of enrolment) or receives during the study must be recorded on the eCRF along with: 
• Reason for use 
• Dates of administration including start and end dates 
• Dosage information including dose and frequency 
The Medical Monitor should be contacted if there are any questions regarding concomitant or prior 
therapy. 
A list of excluded medications/therapy is provided in Appendix 5. 
6.8 
Treatment after the End of the Study 
The Sponsor will not provide any additional care to subjects after they leave the study because 
such care should not differ from what is normally expected for subjects with CRC or GC/GEJ. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 45 of 99 
7.0 DISCONTINUATION OF STUDY TREATMENT AND 
SUBJECT DISCONTINUATION/WITHDRAWAL  
7.1 
Discontinuation of Study Treatment 
7.1.1 
Permanent Discontinuation 
BO-112 should be permanently discontinued when a subject meets 1 of the conditions below or if 
the investigator believes that it is in best interest of the subject: 
• Grade 3 AST/ALT elevation which does not resolve to Grade 2 or less within 1 week of onset 
• Grade 4 AST/ALT increase 
• Grade 3 or 4 increased total bilirubin 
• Clinically significant hepatic bleeding/haematoma in or around injected lesion in the liver. 
Note: Pembrolizumab must also be permanently discontinued in the above situations (see also 
Table 5Error! Reference source not found.), except for hepatic bleeding/haematoma in or a
round injected lesion, where pembrolizumab may be continued as long as the subject is clinically 
stable and there is no confirmed disease progression. 
Individual subject decisions regarding the above may be discussed with the Sponsor in case of a 
clinically stable patient or one who has clinical benefit which needs to be balanced against the 
potential risk of continued or re-instated study treatment. 
BO-112 must be permanently discontinued when a subject meets 1 of the conditions below or if the 
investigator believes that it is in best interest of the subject: 
• Pregnancy: See Appendix 6 and Section 8.3.5 
•  Lost to follow-up 
• Inadvertent enrolment. 
If a subject who does not meet enrolment criteria is inadvertently enroled, that subject must be 
discontinued from study treatment and the Sponsor or Sponsor designee must be contacted. An 
exception may be granted in rare circumstances for which there is a compelling safety reason to 
allow the subject to continue. In these rare cases, the investigator must obtain documented approval 
from the Sponsor or Sponsor designee to allow the subject to continue in the study. Subjects who 
discontinue study treatment will not be replaced. 
See the SoA (Table 1) for data to be collected at the time of treatment discontinuation and follow-
up and for any further evaluations that need to be completed. 
7.1.2 
Rechallenge 
In case of temporary discontinuation, subjects should be placed back on study treatment within 
3 weeks of the scheduled interruption, unless otherwise discussed with the Sponsor (see Section 
6.3). The subjects should be closely monitored for any signs of AEs. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 46 of 99 
7.2 
Subject Discontinuation/Withdrawal from the Study 
• A subject may withdraw from the study at any time at his/her own request or may be withdrawn 
at any time at the discretion of the investigator for safety, behavioural, compliance, or 
administrative reasons. 
• If the subject withdraws consent for disclosure of future information, the Sponsor may retain 
and continue to use any data collected before such a withdrawal of consent. 
• If a subject withdraws from the study, he/she may request destruction of any samples taken 
and not tested, and the investigator must document this in the study center study records. 
• See SoA table (Table 1 in Section 1.3) for data to be collected at the time of study 
discontinuation and follow-up and for any further evaluations that need to be completed. 
7.3 
Lost to Follow-up 
A subject will be considered lost to follow-up if he or she repeatedly fails to return for scheduled 
visits and is unable to be contacted by the study center. 
The following actions must be taken if a subject fails to return to the clinic for a required study 
visit: 
• The study center must attempt to contact the subject and reschedule the missed visit as soon as 
possible and counsel the subject on the importance of maintaining the assigned visit schedule 
and ascertain whether or not the subject wishes to and/or should continue in the study. 
• Before a subject is deemed lost to follow-up, the investigator or designee must make every 
effort to regain contact with the subject (where possible, 3 telephone calls and, if necessary, a 
certified letter to the subject’s last known mailing address or local equivalent methods). These 
contact attempts should be documented in the subject’s medical record. 
• Should the subject continue to be unreachable, he/she will be considered to have withdrawn 
from the study. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 47 of 99 
8.0 STUDY ASSESSMENTS AND PROCEDURES 
A written informed consent will be obtained from the subjects prior to any assessments. Screening 
assessments will be performed according to the SoA. At the enrolment, demographic information 
and medical history will be collected. Subsequent study procedures and their timing are also 
summarised in the SoA (Table 1 in Section 1.3). 
• Protocol waivers or exemptions are not allowed for this study. 
• Adherence to the study design requirements, including those specified in the SoA, is essential 
and required for study conduct. 
• All screening evaluations must be completed and reviewed to confirm that potential subjects 
meet all eligibility criteria. The investigator will maintain a screening log to record details of 
all subjects screened and to confirm eligibility or record reasons for screening failure, as 
applicable. 
• Procedures conducted as part of the subject’s routine clinical management (eg, blood count) 
and obtained before signing of the informed consent form (ICF) may be utilised for Screening 
or baseline purposes provided the procedures met the protocol-specified criteria and were 
performed within the time frame defined in the SoA. 
8.1 
Efficacy Assessments 
Tumour imaging is strongly preferred to be acquired by CT scan. For the abdomen and pelvis, 
contrast-enhanced magnetic resonance imaging (MRI) may be used when CT with iodinated 
contrast is contraindicated, or when mandated by local practice. Magnetic resonance imaging scan 
is the strongly preferred modality for imaging the brain. The same imaging technique regarding 
modality, ideally the same scanner, and the use of contrast should be used in a subject throughout 
the study to optimise the reproducibility of the assessment of existing and new tumour burden and 
improve the accuracy of the assessment of response or progression based on imaging. Imaging 
should include the chest, abdomen, and pelvis. 
Tumour assessments will be conducted at time points stipulated in the SoA (Table 1) based on 
RECIST 1.1. Initial tumour imaging at screening must be performed within 28 days prior to the 
date of treatment allocation. The site study team must review screening images to confirm the 
subject has measurable disease per RECIST 1.1. The first on-study imaging assessment should be 
performed at 6 weeks (42 days ±3 days) from the date of start of treatment. Subsequent tumour 
imaging should be performed every 6 weeks (42 days ±3 days) or more frequently if clinically 
indicated. After 24 weeks (168 days ±7 days), subjects who remain on treatment will have imaging 
performed every 9 weeks (63 days ±7 days). Imaging timing should follow calendar days and 
should not be adjusted for delays in cycle starts. Imaging should continue to be performed until 
disease progression is identified and confirmed by the investigator (iRECIST), the start of new 
anticancer treatment, withdrawal of consent, or death, whichever occurs first. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 48 of 99 
In case of iUPD, a confirmatory CT scan should be done between 4 to 6 weeks after the iUPD scan 
depending on the clinical status of the subject and extent of progression. If this interval is 6 weeks 
after iUPD, this coincides with the next scheduled assessment in the first 24 weeks of the study. If 
disease progression is not confirmed and treatment continues, tumour imaging should resume at 
the next scheduled timepoint ensuring an interval between imaging of at least 6 weeks. 
For subjects who show evidence of radiological PD by RECIST 1.1 as determined by the 
investigator, the investigator will decide whether to continue a subject on study treatment until 
repeat imaging is obtained (using iRECIST for subject management; see Table 6). 
Table 6 
Imaging and Treatment after First Radiologic Evidence of Progressive 
Disease 
 
Clinically Stable 
Clinically Unstable 
Imaging 
Treatment 
Imaging 
Treatment 
First radiologic 
evidence of PD 
by RECIST 1.1  
Repeat imaging 
at 4 to 6 weeks 
to confirm PD. 
May continue study 
treatment at the 
investigator’s 
discretion while 
awaiting 
confirmatory 
tumour imaging by 
site by iRECIST. 
Repeat imaging 
at 4 to 6 weeks 
to confirm PD 
per the 
investigator’s 
discretion only. 
Discontinue treatment 
Repeat tumour 
imaging 
confirms PD 
(iCPD) by 
iRECIST the per 
investigator’s 
assessment 
No additional 
imaging 
required. 
Discontinue 
treatment 
(exception is 
possible upon 
consultation with 
the Sponsor). 
No additional 
imaging 
required. 
Not applicable 
Repeat tumour 
imaging shows 
iUPD by 
iRECIST per the 
investigator’s 
assessment 
Repeat imaging 
at 4 to 6 weeks 
to confirm PD. 
May occur at 
next regularly 
scheduled 
imaging visit. 
Continue study 
treatment at the 
investigator’s 
discretion. 
Repeat imaging 
at 4 to 6 weeks 
to confirm PD 
per 
investigator’s 
discretion only. 
Discontinue treatment 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 49 of 99 
 
Clinically Stable 
Clinically Unstable 
Imaging 
Treatment 
Imaging 
Treatment 
Repeat tumour 
imaging shows 
iSD, iPR, or iCR 
by iRECIST per 
the investigator’s 
assessment. 
Continue 
regularly 
scheduled 
imaging 
assessments. 
Continue study 
treatment at the 
investigator’s 
discretion. 
Continue 
regularly 
scheduled 
imaging 
assessments. 
May restart study 
treatment if condition 
has improved and/or 
clinically stable per 
the investigator’s 
discretion. Next 
tumour imaging 
should occur 
according to the 
regular imaging 
schedule. 
Abbreviations: iCPD = iRECIST confirmed progressive disease; iCR = iRECIST complete response; iRECIST = 
modified Response Evaluation Criteria in Solid Tumours 1.1 for immune-based therapeutics; iSD = iRECIST 
stable disease; iUPD = iRECIST unconfirmed progressive disease; PD = progressive disease; RECIST 1.1 = 
Response Evaluation Criteria in Solid Tumours 1.1.; VOP=verification of progression 
Objective response rate based on best overall response (all time points) using RECIST 1.1 will be 
the primary efficacy endpoint. RECIST 1.1 will be used as the primary measure for assessment of 
tumour response, date of disease progression, and as a basis for all protocol guidelines related to 
disease status except for discontinuation of study treatment. Given the interval of 6 weeks between 
tumour imaging in the first 24 weeks, there is no requirement to confirm objective response within 
4 weeks. 
The hepatic lesion that is the site of BO-112 IT administration, if measurable must be included as 
a target lesion to ensure that any direct effect of the injection is recorded. This lesion(s) will be 
identified as the site of injection and will also be reported separately. 
iRECIST is based on the RECIST 1.1 but adapted to account for the unique tumour response seen 
with immunotherapeutic drugs. iRECIST will be used by the investigator to make treatment 
decisions. When clinically stable, subjects should not be discontinued until progression is 
confirmed by the investigator, according to the rules outlined in Appendix 1. This allowance to 
continue treatment despite initial radiologic PD takes into account the observation that some 
subjects can have a transient tumour flare in the first few months after the start of immunotherapy, 
and then experience subsequent disease response. This data will be captured in the clinical database. 
For the assessments of secondary efficacies or clinical activity of the combination therapy in terms 
of tumour burden and response, following parameters will be determined from CT scan results: 
• Disease control rate comprising best response for CR, PR as well as stable disease (SD) lasting 
at least 12 weeks using RECIST 1.1 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 50 of 99 
• Objective response rate based on best overall response (all time points) using RECIST 
modified for immune-based therapies (iRECIST) 
• Disease control rate comprising best response for CR, PR as well as SD lasting at least 
12 weeks using iRECIST 
• Duration of response 
• PFS 
• Overall survival rate 6 months 
Exploratory efficacy: Immune cell profile of the TME in injected and noninjected lesions and 
genomic analysis of the TME will be done on tumour biopsy samples. See Section 8.8 for further 
details. 
8.2 
Safety Assessments 
Planned time points for all safety assessments are provided in the SoA (Table 1). 
8.2.1 
ECOG Performance Status 
Eastern Cooperative Oncology Group performance status will be measured in a 0 to 5 scale (See 
Appendix 8) at time points stipulated in SoA (Table 1). 
8.2.2 
Physical Examinations 
Physical examination will be performed at time points stipulated in SoA (Table 1). 
• A full physical examination will include, assessments of the skin, cardiovascular, respiratory, 
gastrointestinal, musculoskeletal and neurological systems. Body weight will also be measured 
and recorded. 
• A brief physical examination will include examination of any system that had abnormality at 
previous visits or reported by subjects, as well as assessments of the lungs and abdomen (liver 
and spleen). 
• Investigators should pay special attention to clinical signs related to previous serious illnesses. 
8.2.3 
Vital Signs 
Vital signs will be measured at time points stipulated in SoA (Table 1). 
•  temperature, pulse rate and blood pressure will be assessed. 
• Blood pressure and pulse rate measurements will be assessed with a completely automated 
device. Manual techniques will be used only if an automated device is not available. 
• Blood pressure and pulse measurements should be preceded by at least 5 minutes of rest for 
the subject in a quiet setting without distractions (eg, television, cell phones). 
• Vital signs (to be taken before blood collection for laboratory tests) will consist of 1 pulse rate 
and 3 blood pressure measurements (3 consecutive blood pressure readings will be recorded at 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 51 of 99 
intervals of at least 1 minute). The average of the 3 blood pressure readings will be recorded 
on the eCRF. 
8.2.4 
Electrocardiograms 
Electrocardiogram (ECG) will be performed at time points stipulated in SoA (Table 1). 
• Single 12-lead ECG will be obtained as outlined in the SoA (see Table 1 in Section 1.3) using 
an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and 
QTc intervals. Refer to Section 7.0 for QTc withdrawal criteria and any additional QTc 
readings that may be necessary. 
8.2.5 
Clinical Safety Laboratory Assessments 
A complete list of clinical laboratory tests is provided in Appendix 3. Blood and urine samples 
will be collected at time points stipulated in the SoA (Table 1) and sent to local laboratories as 
appropriate. 
• Safety laboratory assessments will include standard haematology, chemistry, hepatic function, 
CRP, renal function and coagulation parameters, pregnancy tests and thyroid tests. 
• The investigator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the AE section of the eCRF. The 
laboratory reports must be filed with the source documents. Clinically significant abnormal 
laboratory findings are those that are not associated with the underlying disease, unless judged 
by the investigator to be more severe than expected for the subject’s condition. 
• All laboratory tests with values considered clinically significantly abnormal during 
participation in the study or within 28 days after the last dose of study treatment should be 
repeated until the values return to normal or baseline or are no longer considered clinically 
significant by the investigator or Medical Monitor. 
− If such values do not return to normal/baseline within a period of time judged 
reasonable by the investigator, the aetiology should be identified, and the Sponsor 
notified. 
− All protocol-required laboratory assessments, as defined in Appendix 3, must be 
conducted in accordance with the laboratory manual and the SoA. 
− If laboratory values from non-protocol specified laboratory assessments performed at 
the institution’s local laboratory require a change in subject management or are 
considered clinically significant by the investigator (eg, SAE or AE or dose 
modification), then the results must be recorded in the eCRF. 
8.3 
Adverse Events 
The definitions of an AE or SAE can be found in Appendix 4. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 52 of 99 
Adverse events will be reported by the subject (or, when appropriate, by a caregiver, surrogate, or 
the participant's legally authorised representative). 
The investigator and any designees are responsible for detecting, documenting, and recording 
events that meet the definition of an AE or SAE and remain responsible for following up AEs that 
are serious, considered related to the study treatment or study procedures, or that caused the subject 
to discontinue the study treatment or the study (see Section 7.0). 
8.3.1 
Time Period and Frequency for Collecting AE and SAE Information 
• 
All AEs or ECIs (Events of Clinical Interest) from the time of treatment start through 30 days 
following cessation of study treatment must be reported by the investigator. All AEs will be 
collected at the time points specified in the SoA (Section 1.3). 
• 
All AEs meeting serious criteria, from the time of treatment start through 90 days following 
cessation of study treatment, or 30 days following cessation of study treatment if the participant 
initiates new anticancer therapy, whichever is earlier must be reported by the investigator. All 
SAEs will be collected at the time points specified in the SoA (Section 1.3). 
• 
All pregnancies and exposure during breastfeeding, from the time of treatment/ allocation 
through 120 days following cessation of study treatment, or 30 days following cessation of 
study treatment if the participant initiates new anticancer therapy must be reported by the 
investigator. 
Medical occurrences that begin before the start of study treatment but after obtaining informed 
consent will be recorded on the medical history/Current Medical Conditions section of the ECRF, 
not the AE section. 
All SAEs will be recorded and reported to the Sponsor or designee within 24 hours, as indicated 
in Appendix 4. The investigator will submit any updated SAE data to the Sponsor within 24 hours 
of it being available. 
Investigators are not obligated to actively seek AE or SAE after conclusion of the study 
participation. However, if the investigator learns of any SAE, including a death, at any time after 
a subject has been discharged from the study, and he/she considers the event to be reasonably 
related to the study treatment or study participation, the investigator must promptly notify the 
Sponsor. 
The method of recording, evaluating, and assessing causality of AE and SAE and the procedures 
for completing and transmitting SAE reports are provided in Appendix 4. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 53 of 99 
8.3.2 
Method of Detecting AEs and SAEs 
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and 
non-leading verbal questioning of the subject is the preferred method to inquire about 
AE occurrences. 
8.3.3 
Follow-up of AEs and SAEs 
After the initial AE/SAE report, the investigator is required to proactively follow each subject at 
subsequent visits/contacts. All SAEs will be followed until resolution, stabilisation, the event is 
otherwise explained, or the subject is lost to follow-up (as defined in Section 7.3). Further 
information on follow-up procedures is given in Appendix 4. 
8.3.4 
Regulatory Reporting Requirements for SAEs 
• Prompt notification by the Investigator to the Sponsor of an SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of subjects and the safety of a study 
treatment under clinical investigation are met. 
• The Sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study treatment under clinical investigation. The 
Sponsor will comply with country-specific regulatory requirements relating to safety reporting 
to the regulatory authority, Independent Ethics Committees (IECs), and investigators. 
• Investigator safety reports must be prepared for suspected unexpected serious adverse reactions 
(SUSAR) according to local regulatory requirements and Sponsor policy and forwarded to 
investigators as necessary. 
• An investigator who receives an investigator safety report describing an SAE or other specific 
safety information (eg, summary or listing of SAEs) from the Sponsor will review and then 
file it along with the Investigator’s Brochure and will notify the IEC, if appropriate according 
to local requirements. 
8.3.5 
Pregnancy 
• Details of all pregnancies in female subjects and, if indicated, female partners of male subjects 
will be collected after the start of study treatment and until 120 days after the last dose. 
• If a pregnancy is reported, the investigator should inform the Sponsor within 24 hours of 
learning of the pregnancy and should follow the procedures outlined in Appendix 7. 
• Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy) are considered SAEs. 
8.3.6 
Events of Clinical Interest 
Selected non-serious and serious adverse events are also known as Events of Clinical Interest (ECI) 
and must be reported to the Sponsor. 
Events of clinical interest for this trial include:  

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 54 of 99 
• An overdose of BO-112 and/or pembrolizumab, as defined in Section 8.4, that is not associated 
with clinical symptoms or abnormal laboratory results. 
• An elevated AST or ALT lab value that is greater than or equal to 3x the upper limit of normal 
and an elevated total bilirubin lab value that is greater than or equal to 2x the upper limit of 
normal and, at the same time, an alkaline phosphatase lab value that is less than 2x the upper 
limit of normal, as determined by way of protocol-specified laboratory testing or unscheduled 
laboratory testing.* 
*Note:  These criteria are based upon available regulatory guidance documents. The purpose of 
the criteria is to specify a threshold of abnormal hepatic tests that may require an additional 
evaluation for an underlying etiology. The trial site guidance for assessment and follow up of these 
criteria can be made available. It may also be appropriate to conduct additional evaluation for an 
underlying etiology in the setting of abnormalities of liver blood tests including AST, ALT, 
bilirubin, and alkaline phosphatase that do not meet the criteria noted above. In these cases, the 
decision to proceed with additional evaluation will be made through consultation between the 
study investigators and the Sponsor. However, abnormalities of liver blood tests that do not meet 
the criteria noted above are not ECIs for this trial. 
8.3.7 
Disease-related Events and/or Disease-related Outcomes Not Qualifying as SAEs 
The following disease-related events (DREs) are common in subjects with colorectal and GC/GEJ 
cancer and can be serious/life-threatening: 
• Signs and symptoms unambiguously associated with disease progression. 
• Death due to disease progression. 
Because these events are associated with the disease under study, they will not be reported 
according to the standard process for expedited reporting of SAEs even though the event may meet 
the definition of a SAE. These events will be recorded on the corresponding AE page of the 
subject’s eCRF within 14 days. 
NOTE: However, if either of the following conditions applies, then the event must be recorded and 
reported as an SAE (instead of a DRE): 
• The event is, in the investigator’s opinion, of greater intensity, frequency, or duration than 
expected for the individual subject. 
OR 
• The investigator considers that there is a reasonable possibility that the event was related to 
study treatment. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 55 of 99 
8.4 
Treatment of Overdose 
For this study, an overdose of pembrolizumab will be defined as any dose of 1000 mg or ≥ 5 times 
the indicated dose. For BO-112 the definition of overdose is difficult since administration is via 
IT injections and to date there are no detectable levels of BO-112 systemically. The potential risk 
of overdose will likely come from leakage from the injected tumour into circulation and this may 
be volume related. Note there is only 1 dose/volume allowed (1 mg in 1.7 mL) in this protocol. An 
overdose is therefore defined for this protocol as an IT injection volume in mL which exceeds the 
approximate volume of the tumour and this would become applicable for injected lesions that have 
a diameter of < 15 mm since the corresponding volume of a sphere with this diameter is 
approximately 1.8 mL. In addition, any dose (inadvertently) administered outside of the intended 
tumoural lesion into normal liver tissue will be considered an overdose. 
No specific information is available on the treatment of overdose of pembrolizumab or BO-112. 
In the event of overdose, the subject should be observed closely for signs of toxicity. Appropriate 
supportive treatment should be provided if clinically indicated. 
Sponsor does not recommend specific treatment for an overdose. 
In the event of an overdose, the investigator/treating physician should: 
1. Contact the Medical Monitor immediately. 
2. Document the quantity/description of the excess dose as well as the duration of the overdose 
in the eCRF. 
Decisions regarding dose interruptions or modifications will be made by the investigator in 
consultation with the Medical Monitor based on the clinical evaluation of the subject. 
8.5 
Pharmacokinetics 
• Plasma samples of approximately 3 mL will be collected to evaluate if BO-112 is detectable 
in plasma concentrations of BO-112 as specified in the SoA (Table 1). A baseline sample will 
be collected at Visit 1a (Cycle 1 – Day 1) at the same time as the baseline safety laboratory 
tests, namely before the first treatment with pembrolizumab. A unique sample will be collected 
during the study at Visit 1a (Cycle 1 – Day 1). This PK sample must be taken 30 to 60 minutes 
after the first BO-112 administration. Instructions for the collection and handling of biological 
samples will be provided by the Sponsor. The actual date and time (24-hour clock time) of 
each sample will be recorded. The time and date of study treatment administration will also be 
recorded. 
• Samples will be used to evaluate the PK of BO-112 after first IT injection for systemic 
exposure. Samples collected for analyses of BO-112 plasma concentration may also be used 
to evaluate safety or efficacy aspects related to concerns arising during or after the study. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 56 of 99 
Any changes in the timing or addition of time points for any planned study assessments must be 
documented and approved by the relevant study team member and then archived in the Sponsor 
and study center study files but will not constitute a protocol amendment. The IEC will be informed 
of any safety issues that require alteration of the safety monitoring scheme or amendment of the 
ICF. 
8.6 
Pharmacodynamics 
Evaluation procedure of antitumoural and immunological effects of BO-112 in the TME of the 
injected lesion has been described in Section 8.8. 
8.7 
Genetics 
Not applicable to this study. 
8.8 
Biomarkers 
• The following samples for biomarker research are required and will be collected from all 
subjects in this study as specified in the SoA (Table 1): 
− Tumour biopsy samples to be collected at the same intervention as the BO-112 
administration at the applicable visit. 
• Samples will be tested for evaluation of antitumoural effects of BO-112 in the TME of the 
injected lesion. 
Samples may be stored for a maximum of 5 years (or according to local regulations) following the 
last subject’s last visit for the study at a facility selected by the Sponsor to enable further analysis 
of biomarker responses to BO-112. 
8.8.1 
Immune Cell Profile of the Tumour Microenvironment 
Immune cell profile of the TME in BO-112 injected and noninjected lesions will be evaluated in 
biopsy samples collected from all subjects according to the SoA. These samples will be tested by 
the Sponsor or Sponsor’s designee. 
The detection and characterisation of the immune cell profile of the TME in BO-112 injected and 
noninjected lesions will be performed using an immunohistochemistry method by or under the 
supervision of the Sponsor. Samples may be stored for a maximum of 5 years (or according to 
local regulations) following the last subject’s last visit for the study at a facility selected by the 
Sponsor to enable further analysis of immune responses to BO-112. 
8.8.2 
DNA Research 
DNA studies will be conducted to analyze the tumor microenvironment with the aim of  gain 
insights into the activation of the immune response and  identify possible biomarkers related to the 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 57 of 99 
efficacy of BO-112.  The samples may also be used to confirm findings by application of 
alternative technologies. 
8.9 
Health Economics OR Medical Resource Utilisation and Health 
Economics 
Health Economics/Medical Resource Utilisation and Health Economics parameters are not 
evaluated in this study. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 58 of 99 
9.0 STATISTICAL CONSIDERATIONS 
9.1 
Statistical Hypotheses and Sample Size Determination 
Approximately 80 subjects will be screened to achieve a total of 69 evaluable subjects. For both 
Cohort A (CRC) and Cohort B (GC/GEJ), subjects must have MSS (pMMR) disease to be 
considered evaluable for efficacy. This will be determined during the study and therefore subjects 
with MSI (dMMR) disease will be replaced. Given the low incidence of dMMR in stage IV CRC 
and in GC/GEJ, it is expected that this number will be low, ie, approximately 1 to 2 subjects to be 
replaced per cohort. Subjects with dMMR disease will be included in the safety analysis set. 
The sample sizes of the cohorts were determined using Simon’s 2-stage design 39 to enable a first 
evaluation of the treatment’s activity on tumour response. The designs are based on a one-sided 
 = 0.05; a power 80% and response probabilities based on RECIST 1.1 noted below. 
When the prespecified number of subjects for Stage 1 have been enroled and have reached the first 
on-study response assessment, an interim review of available data will be done by a DMC per 
cohort. The DMC will take the number of responses defined by the Simon’s 2-stage design into 
consideration together with the ORR, DCR, number of subjects with Grade 3 to 5 AEs, SAEs, and 
individual subject tumour burden profiles to make a reasoned recommendation to the Sponsor 
regarding extension of each cohort to the foreseen total number of subjects. The stopping rules for 
futility based on the observed number of responses are considered nonbinding, leaving the final 
recommendation for stopping the study after Stage 1 at the discretion of the DMC members. 
• Cohort A (CRC): response probability based on RECIST 1.1 of P0 = 1% (for anti-PD1 
monotherapy in MSS CRC: ORR of 0% based on RECIST 1.1 for pembrolizumab 4,5) to be 
tested against the alternative (desirable) response probability of P1 = 15%. For the first stage, 
11 subjects* (N1) will be enroled and if no responses are observed, the study will be stopped 
for futility. In case there is no treatment effect (P1=P0 = 1%), the study entails a 90% chance 
of early stopping (after Stage 1). If 1 or more responses are observed, an additional 15 subjects* 
(N2) will be enroled for a total of N = 26 subjects. If 2 or more subjects have a response, then 
the study will have shown that with 95% confidence, the response probability is above 1%. 
For 2 responses, the observed response rate is 7.7% and the 90% exact confidence interval (CI) 
is [5.8%, 10.9%]. However, accounting for the adaptive 2-stage feature of the design, the 
corrected 90% CI is [1.7%, 24.2%] 40. 
* The baseline biopsy sample will be evaluated for pMMR (as proxy of MSS) versus dMMR 
(as proxy of MSI-H) status in Cohort A and subjects who are MSI-H/dMMR will be replaced 
to ensure the appropriate number of pMMR subjects for the statistical analysis. Data from 
subjects with dMMR CRC will be evaluated as part of the safety population for safety 
parameters, but separately and descriptively for efficacy endpoints. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 59 of 99 
• Cohort B (GC/GEJ): response probability based on RECIST 1.1 of P0 = 10% (expected under 
anti-PD1 monotherapy where pembrolizumab treatment has achieved ORR based on 
RECIST 1.1 of 12%, 9) to be tested against the alternative (desirable) response probability 
P1 = 25%. For the first stage, 18 subjects** (N1) will be enroled and if 2 or less responses are 
observed, the study will be stopped for futility. In case there is no treatment effect 
(P1=P0= 10%), the study entails a 73% chance of early stopping (after Stage 1). If 3 or more 
responses are observed, an additional 25 subjects** (N2) will be enroled for a total of N = 43 
subjects. If 8 or more subjects have a response, then the study will have shown that with 95% 
confidence, the response probability is above 10%. Note that for 8 responses, the observed 
response rate is 18.6% with 90% exact CI [17.0%, 20.8%]. However, accounting for the 
adaptive 2-stage feature of the design, the corrected 90% CI is [10.1%, 32.1%] 40. 
** The baseline biopsy sample will be evaluated for pMMR (as proxy of MSS) versus dMMR  
(as proxy of MSI-H) status in Cohort B and subjects who are MSI-H/dMMR will be replaced 
to ensure the appropriate number of pMMR subjects for the statistical analysis. Data from 
subjects with dMMR GC/GEJ will be evaluated as part of the safety population for safety 
parameters, but separately and descriptively for efficacy endpoints. The baseline biopsy sample 
will be evaluated for PD-L1 status in Cohort B; however, there will be no replacement of 
subjects based on this since the ORR reported the PD-L1 positive subgroup is 15.5% and for 
the PD-L1 negative subgroup is 6.4% 9. 
9.2 
Populations for Analyses 
For purposes of analysis, the analysis sets in Table 7 are defined. 
Table 7 
Analysis Sets 
Analysis Set 
Description 
Entered Analysis Set 
All subjects who sign the informed consent form. 
Full Analysis Set 
All enroled subjects who receive at least 1 dose of study treatment (BO-112 or 
pembrolizumab). pMMR and dMMR subjects will be evaluated separately for 
efficacy endpoints. dMMR subjects will only be analysed descriptively for 
efficacy endpoints. 
Safety Analysis Set 
All enroled subjects who receive at least 1 dose of study treatment (BO-112 or 
pembrolizumab), i.e. same population as FAS. dMMR subjects will be 
evaluated together with pMMR subjects for safety endpoints. 
9.3 
Statistical Analyses 
The Statistical Analysis Plan (SAP) will be developed and finalised before interim database lock 
and will describe the subject analysis sets to be included in the analyses, and procedures for 
accounting for missing, unused, and spurious data. This section is a summary of the planned 
statistical analyses of the primary and secondary endpoints. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 60 of 99 
All analyses, summaries, and listings will be performed using SAS® software (version 9.4 or 
higher). 
The following descriptive statistics will be used as applicable to summarise the study data unless 
otherwise specified: 
• Continuous variables: sample size (n), mean, standard deviation (SD), median, minimum 
(min), and maximum (max). 
• Categorical variables: frequencies and percentages. 
Individual subject data will be presented in listings. 
9.3.1 
Efficacy Analyses 
Analyses of efficacy will be conducted separately for each cohort based on all subjects included 
in the Full Analysis Set. In Cohort A, subjects who are dMMR will be evaluated separately and 
descriptively only. See Table 8 below. 
Table 8 
Efficacy Analyses 
Endpoint 
Statistical Analysis Methods 
Primary 
Objective Response Rate based on RECIST 1.1 is defined as the percentage of 
subjects with CR or PR as BOR according to RECIST 1.1. The number and 
percentage of responders, subjects with CR or PR as BOR, and of non-responders 
subjects with SD, PD or NE as BOR, will be provided along with 95% CI for ORR. 
In addition, number and percentage of subjects with CR, PR, SD, PD and 
non-evaluable (NE) as BOR according to RECIST 1.1 will be provided. 
Secondary 
Disease Control Rate (DCR) based on RECIST 1.1 is defined as the percentage of 
subjects with CR or PR, and the percentage of subjects with SD of at least 
12 weeks duration, as BOR according to RECIST 1.1. The number and percentage 
of subjects achieving disease control, subjects with CR or PR or SD as BOR, and 
not achieving disease control, subjects with PD or NE as BOR, will be provided 
along with 95% CI for DCR. 
• 
ORR according to RECIST modified for immune-based therapies (iRECIST) 
is defined as the percentage of subjects with iCR or iPR as best overall 
response (iBOR) according to iRECIST. The number and percentage of 
responders, subjects with iCR or iPR as iBOR, and of non-responders, subjects 
with iSD, iUPD, iCPD or NE as iBOR, will be provided along with 95% CI for 
ORR. In addition, number and percentage of subjects with iCR, iPR, iSD, 
iUPD, iCPD and NE as iBOR according to iRECIST will be provided. 
• 
DCR according to iRECIST is defined as the percentage of subjects with iCR or 
iPR or iSD of at least 12 weeks duration as best overall response according to 
iRECIST. The number and percentage of subject achieving disease control, 
subjects with iCR or iPR or iSD as iBOR, and not achieving disease control, 
subjects with iUPD or iCPD or NE as iBOR, will be provided along with 95% 
CI for DCR. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 61 of 99 
• 
DOR according to RECIST 1.1 is defined as the time in months from the date of 
first documented response (ie, overall response = CR or PR) to the earlier 
between the date of first documented progression (ie, overall response= PD) and 
the date of death. DOR will be analysed using Kaplan-Meier method. Kaplan-
Meier estimate of median DOR will be provided with the 95% Cis. Kaplan-
Meier DOR curve will be plotted. 
• 
PFS according to RECIST 1.1 is defined as the time in months from first dose 
of study treatment (any agent) to first documented radiologic progression or 
death, whichever occurs first. Subjects without documented radiologic 
progression or death event will be censored at last evaluable postbaseline tumour 
assessment. The number and percentage of subjects who were progression-free, 
who progressed, who died and censored for PFS will be provided. Kaplan-Meier 
estimate of median PFS will be provided with the 95% Cis. The proportion of 
subjects who survived progression-free for at least 12 weeks will be provided 
along with 95% CI. Kaplan-Meier PFS curve will be plotted. 
• 
OS is defined as the time in months from first dose of study treatment (any agent) 
to death. Subjects without documented death event will be censored at the date 
he/she was last known to be alive. The number and percentage of subjects who 
died and censored for OS will be provided. Kaplan-Meier estimate of median 
OS will be provided with the 95% Cis. The proportion of subjects who survived 
for at least 6 months will be provided along with 95% CI. Kaplan-Meier OS 
curve will be plotted. 
 
Exploratory 
Will be described in the SAP finalised before interim database lock. 
Abbreviations: BOR=best overall response; CI=confidence interval; DCR=disease control rate; 
DOR=duration of overall response; iRECIST= RECIST modified for immune-based therapies; PR= 
partial response; RECIST= Response evaluation criteria in solid tumours; SD=stable disease; 
ORR=overall response rate; OS=overall survival. 
Note: the prefix “i” denotes immune-related or immune-based. 
 
9.3.2 
Safety Analyses 
All safety analyses will be performed on the safety analysis set separately for each cohort. In 
Cohort A, subjects who are dMMR will be evaluated together with pMMR subjects. 
Treatment-emergent adverse events are defined as AEs that first occurred or worsened in severity 
after the first administration of study treatment and prior to 30 days after the last administration of 
study treatment. 
Adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA). 
Numbers of TEAEs and incidence rates will be tabulated by preferred term and system organ class. 
Treatment-emergent AEs of any grade, TEAEs with severity ≥ Grade 3 (NCI-CTCAE v 5.0), 
TEAEs (any grade) by relationship to study treatment, TEAEs related (probable, possible or 
unknown causality) to study treatment with severity ≥ Grade 3 (NCI-CTCAE v 5.0) SAEs, TEAEs 
leading to death, and TEAEs leading to discontinuation of study treatment will be tabulated for the 
number and proportion of subjects. Additionally, treatment tolerability will be determined by the 
number of study discontinuations due to treatment-related TEAEs. Commonly occurring TEAEs, 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 62 of 99 
ie, those that occur in 5% or more of the subjects in either treatment group, will be summarised 
using descriptive statistics. 
All laboratory test results, vital signs measurements, ECG results, weight, and body mass index 
will be summarised using descriptive statistics at each visit for raw numbers and change from 
baseline. The incidence of treatment-emergent abnormal laboratory, vital sign, and ECG values 
will also be summarised using descriptive statistics. 
9.3.3 
Other Analyses 
Biomarker exploratory analyses will be described in the SAP. Pharmacokinetic analyses are 
expected to be limited since no systemic exposure is expected from IT injection of BO-112. There 
will be no PK analysis of pembrolizumab. Therefore, the PK analysis will be described in the SAP. 
9.3.4 
Missing, Unused and Spurious Data 
Statistical analysis will be performed using available data only; missing values will not be imputed. 
Data from subjects who withdraw from the study, including AEs and any follow-up, will be 
included in the analyses of primary and secondary outcomes. 
9.4 
Interim Analyses 
An interim analysis for futility will be carried out in each cohort separately when the prespecified 
number of subjects for Stage 1 have been enroled and have reached at least the first on-study 
response assessment. Enrolment will be suspended per cohort at the Stage 1 sample size pending 
the outcome of the DMC review. The DMC will review the safety and efficacy data per cohort. 
The number of responses together with the ORR, DCR, number of subjects with Grade 3 to 5 AEs, 
SAEs and individual subject tumour burden profiles will be taken into account to make a reasoned 
recommendation to the Sponsor regarding extension of each cohort to the foreseen total number 
of subjects. The stopping rules for futility based on the observed number of responses are defined 
in Section 9.2 and considered non-binding, leaving the final recommendation for stopping the 
study after Stage 1 at the discretion of the DMC members 
The SAP will describe the planned interim analyses in greater detail. 
9.5 
Data Monitoring Committee 
A DMC consisting of members who are independent from the Sponsor will be established. The 
DMC membership will have 3 members, including specialists with expertise in CRC, gastric/GEJ 
cancer and immuno-oncology. The study statistician will provide statistical support. 
When the prespecified number of subjects for Stage 1 have been enroled and have reached at least 
the first on-study response assessment, the DMC will review the safety and efficacy data per 
cohort. Enrolment will be suspended per cohort and the DMC will review the safety and efficacy 
data available at the time that the last subject enrolled has reached the first on-study response 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 63 of 99 
assessment at Week 7 (= Cycle 3). The DMC will make a recommendation to the Sponsor 
separately for each cohort regarding expanding to the total foreseen sample size. 
The DMC will be responsible for making recommendations as to whether it is scientifically and 
ethically appropriate to continue enrolment, discontinue treatment groups, or stop the study. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 64 of 99 
10.0 REFERENCES 
1. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid 
tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47. 
2. Keytruda US package insert, www.accessdata.fda.gov, accessed 15 March 2019. 
3. Opdivo US package insert, www.accessdata.fda.gov, accessed 15 March 2019. 
4. Le DT, Uram JN, Wang H, et al. PD-1 Blockade in tumours with mismatch-repair 
deficiency. N Engl J Med.2015; 372(26):2509-2520 
5. O’Neil BH, Wallmark JM, Lorente D, et al. Safety and antitumour activity of the anti-PD-
1 antibody pembrolizumab in patients with advanced colorectal carcinoma. PloS 
One.2017; 12(12): e0189848. 
6. Koopman M, Kortman GA, Mekenkamp L, et al. Deficient mismatch repair system in 
patients with sporadic advanced colorectal cancer. Br J Cancer.2009; 100(2):266-273. 
7. Llosa NJ, Cruise M, Tam A, et al. The Vigorous Immune Microenvironment of 
Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory 
Checkpoints. Cancer Discovery. 2014;5:43-51. 
8. Stivarga 
European 
public 
assessment 
report 
(EPAR), 
www.ema.europa.eu/en/medicines/human/EPAR/stivarga, accessed 15 March 2019. 
9. Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in 
patients with previously treated advanced gastric and gastroesophageal junction cancer, 
Phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4(5):1-8. 
10. Halama N, Michel S, Kloor M, et al. Localization and density of immune cells in the 
invasive margin of human colorectal cancer liver metastases are prognostic for response to 
chemotherapy. Cancer Res.2011;71 (17):5670-5677. 
11. Mlecnik B, Van den Eynde M, Bindea G, et al. Comprehensive Intrametastatic Immune 
Quantification and Major Impact of Immunoscore on Survival. J Natl Cancer Inst.2018; 
110:97-108. 
12. Tu Z, Bozorgzadeh A, Pierce RH, Kurtis J, Crispe IN, Orloff MS, et al. TLR-dependent 
cross talk between human Kupffer cells and NK cells. J Exp Med.2008;205(1):233-244. 
13. Horst AK, Neumann K, Diehl L, Tiegs G, et al. Modulation of liver tolerance by 
conventional and nonconventional antigen-presenting cells and regulatory immune cells. 
Cell Mol Immunol.2016;13 (3):277-292. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 65 of 99 
14. Lang KS, Georgiev P, Recher M, et al. Immunoprivileged status of the liver is controlled 
by Toll-like receptor 3 signaling. J Clin. Invest. 2006;116:2456–2463. 
15. Aznar, MA, Planelles, L, Perez-Olivares M, et al. Immunotherapeutic effects of 
intratumoural nanoplexed poly I:C. J Immunother Cancer.2019;2;7(1):116. 
16. Disis ML. Immune Regulation of Cancer. J Clin Oncol.2010; 28 (29):4531-38. 
17. Dudley ME, Wunderlich JE, Yang JC, et al. Adoptive Cell Transfer Therapy Following 
Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients 
With Refractory Metastatic Melanoma. J Clin Oncol.2005;0732-183. 
18. Hunder NN, Wallen H, Cao J, et al. Treatment of metastatic melanoma with autologous 
CD4+ T cells against NY-ESO-1. N Engl J Med. 2008;358(25):2698-703. 
19. Greenwald RJ., Freeman G J., and Sharpe A H. The B7 Family Revisited. Annu Rev 
Immunol.2005;23:515–48. 
20. Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. PD-1 immunoreceptor inhibits 
B cell receptor-mediated signaling by recruiting src homology 2-domain-containing 
tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A. 2001;98(24):13866-
71. 
21. Zhang, X, Schwartz JC, Guo X, et al. Structural and Functional Analysis of the 
Costimulatory Receptor Programmed Death-1. Immunity.2004; 337-347. 
22. Chemnitz JM, Parry RV., Nichols KE., June, CH., Riley JL. SHP-1 and SHP-2 Associate 
with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary 
Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation. J 
Immunol.2004, 173: 945–954. 
23. Shepard KA, Fitz LJ, Lee JM, et al. PD-1 inhibits T-cell receptor induced phosphorylation 
of the ZAP70/CD3 signalosome and downstream signaling to PKC. FEBS Letters. 
2004;0014-5793. 
24. Riley JL. PD-1 signaling in primary T cells. Immunol Rev. 2009;0105-2896. 
25. Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA-4 and PD-1 Receptors Inhibit T-Cell 
Activation by Distinct Mechanisms. Mol and Cell Biol, 2005;0270-7306. 
26. Francisco LM., Sage PT, and Sharpe AH. The PD-1 pathway in tolerance and 
autoimmunity. Immunol Rev.2010;0105-2896. 
27. Hirano F, Kaneko K, Tamura H, et al., Blockade of B7-H1 and PD-1 by monoclonal 
antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005;65(3):1089-96. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 66 of 99 
28. Blank, C, Brown I, Peterson AC, et al. PD-L1/B7H-1 inhibits the effector phase of tumour 
rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2004; 64(3): 
1140-5. 
29. Weber, J., Immune checkpoint proteins: a new therapeutic paradigm for c—cer—
preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol. 2010; 37(5): 430-9. 
30. Strome SE, Dong H, Tamura H, et al. B7-H1 blockade augments adoptive T-cell 
immunotherapy for squamous cell carcinoma. Cancer Res. 2003; 63(19): 6501-5. 
31. Spranger S., Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF et al. Mechanism 
of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves 
restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor 
microenvironment. J Immunother Cancer. 2014; 2: 3. 
32. Curran MA, Montalvo W, Yagita H, Allison JP et al., PD-1 and CTLA-4 combination 
blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within 
B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010; 107(9): 4275-80. 
33. Pilon-Thomas S, Mackay A, Vohra N, Mule JJ. Blockade of programmed death ligand 1 
enhances the therapeutic efficacy of combination immunotherapy against melanoma. 
J Immunol, 2010; 184(7): 3442-9. 
34. Nomi T, Sho M, Akahori T, et al. Clinical significance and therapeutic potential of the 
programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. 
Clin Cancer Res. 2007; 13(7): 2151-7. 
35. Marquez-Rodas I, Rodriguez Ruiz ME, Lopez-Tarruella Cobo S, et al. Safety and 
immunobiological activity of intratumoral (IT) double-stranded RNA (dsRNA) BO-112 in 
solid malignancies: first in human clinical trial. 2017; Poster presented at European Society 
for Medical Oncology (ESMO LBA20). 
36. Marquez-Rodas I, Longo F, Rodriguez Ruiz M, et al. Intratumoral BO-112, a double-
stranded RNA, alone and in combination with systemic anti-PD-1 in solid tumors. 2018; 
Poster presented at (ESMO LBA39). 
37. Oken M, Creech R, Tormey D, et al. Toxicity and response criteria of the Eastern 
Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655. 
38. Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use 
in trials testing immunotherapeutics. Lancet Oncol.2017;18(3):e143-52. 
39. Simon R. Optimal Two-Stage Designs for Phase II Clinical Trials. Control Clin 
Trials.1989;10 (1):1-10. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 67 of 99 
40. Koyama T and Chen H. Proper inference from Simon’s 2-stage designs. Statistics in 
Medicine.2008;27(16):3145-3154. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 68 of 99 
11.0 APPENDICES 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 69 of 99 
Appendix 1 
Abbreviations 
Abbreviation 
Definition 
AE 
Adverse event 
ALT 
Alanine aminotransferase 
AST 
Aspartate aminotransferase 
BOR 
Best overall response  
CI 
Confidence interval 
CR 
Complete response 
CRC 
Colorectal cancer 
CRO 
Contract research organisation 
CRP 
C-reactive protein 
CT 
Computed tomography 
CTCAE 
Common Terminology Criteria for Adverse Events 
DCR 
Disease control rate 
DMC 
Data monitoring committee 
dMMR 
Deficient mismatch repair 
DRE 
Disease-related event 
ECG 
Electrocardiogram 
ECOG PS 
Eastern Cooperative Oncology Group Performance Status 
eCRF 
Electronic case report form 
EGFR 
Epidermal growth factor receptor 
EOS 
End of Study 
GC/GEJ 
Gastric or gastro-oesophageal junction cancer 
GCP 
Good Clinical Practice 
ICF 
Informed consent form 
ICH 
International Council for Harmonisation 
iCPD 
Confirmed progressive disease 
IEC 
Independent Ethics Committee 
IFN 
Interferon 
Ig 
Immunoglobulin 
irAE 
Immune-related adverse event 
iRECIST 
RECIST modified for immune-based therapies 
IT 
Intratumoural 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 70 of 99 
Abbreviation 
Definition 
DNA 
Deoxyribonucleic acid 
iUPD 
Immune unconfirmed progressive disease 
IV 
Intravenous (ly) 
mAb 
Monoclonal antibody 
mPFS 
Median progression-free survival 
MSI 
Microsatellite instability 
MSI-H 
Microsatellite instability-high 
MSS 
Microsatellite stability 
NCI 
National Cancer Institute 
NSCLC 
Non-small cell lung cancer 
ORR 
Objective response rate 
PD1 
Programmed cell death Protein 1 
PDL 
Programmed cell death ligand 
PEI 
Polyethyleneimine 
PFS 
Progression-free survival 
PK 
Pharmacokinetics 
pMMR 
Proficient mismatch repair 
Poly I:C 
polyinosinic-polycytidylic acid 
PR 
Partial response 
Q2W 
Once every 2 weeks 
Q3W 
Once every 3 weeks 
RBC 
Red blood cell 
RECIST 
Response evaluation criteria in solid tumours 
 
 
SAE 
Serious adverse event 
SAP 
Statistical Analysis Plan 
SCCHN 
Squamous cell carcinoma of the head and neck 
SD 
Stable disease 
SoA 
Schedule of Assessments 
TEAE 
Treatment-emergent adverse event 
TME 
Tumour microenvironment 
ULN 
Upper limit of normal 
V 
Visit 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 71 of 99 
Abbreviation 
Definition 
W 
Week 
WOCBP 
Woman of childbearing potential 
 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 72 of 99 
Appendix 2 
Regulatory, Ethical, and Study Oversight Considerations 
Regulatory and Ethical Considerations 
• This study will be conducted in accordance with the protocol and with the following: 
− Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organisations of Medical 
Sciences (CIOMS) International Ethical Guidelines. 
− Applicable International Council for Harmonisation (ICH) Good Clinical Practice 
Guidelines. 
− Applicable laws and regulations. 
• The protocol, protocol amendments, ICF, Investigator’s Brochure, and other relevant 
documents (eg, advertisements) must be submitted to an IEC by the investigator and reviewed 
and approved by the IEC before the study is initiated. 
• Any amendments to the protocol will require IEC and regulatory authority approval, when 
applicable, before implementation of changes made to the study design, except for changes 
necessary to eliminate an immediate hazard to subjects. 
• The investigator will be responsible for the following: 
− Providing written summaries of the status of the study to the IEC annually or more 
frequently in accordance with the requirements, policies, and procedures established 
by the IEC. 
− Notifying the IEC of SAEs or other significant safety findings as required by IEC 
procedures. 
− Providing oversight of the conduct of the study at the study center and adherence to 
requirements of 21 Code of Federal Regulations (CFR), ICH guidelines, the IEC, 
European regulation 536/2014 for clinical studies (if applicable), and all other 
applicable local regulations. 
• After reading the protocol, each investigator will sign the protocol signature page and send a 
copy of the signed page to the Sponsor or representative (Appendix 10). The study will not 
start at any study center at which the investigator has not signed the protocol. 
Financial Disclosure 
Investigators and sub-investigators will provide the Sponsor with sufficient, accurate financial 
information as requested to allow the Sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators are 
responsible for providing information on financial interests during the course of the study and for 
1 year after completion of the study. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 73 of 99 
Insurance 
Sponsor will provide insurance in accordance with local guidelines and requirements as a 
minimum for the subjects in this study. The terms of the insurance will be kept in the study files. 
Informed Consent Process 
• The investigator or his/her representative will explain the nature of the study to the subject or 
his/her legally authorised representative and answer all questions regarding the study. 
• Subjects must be informed that their participation is voluntary. Subjects will be required to 
sign a statement of informed consent that meets the requirements of local regulations, ICH 
guidelines, and the IEC or study center. 
• The medical record must include a statement that written informed consent was obtained before 
the subject was entered in the study and the date the written consent was obtained. The 
authorised person obtaining the informed consent must also sign the ICF. 
• Subjects must be re-consented to the most current version of the ICF(s) during their 
participation in the study. 
• A copy of the ICF(s) must be provided to the subject or the subject’s legally authorised 
representative. 
A subject who is rescreened is not required to sign another ICF if the rescreening occurs within 
28 days from the previous ICF signature date. 
The ICF will contain a separate section that addresses the use of remaining mandatory samples for 
optional exploratory research. The investigator or authorised designee will explain to each subject 
the objectives of the exploratory research. Subjects will be told that they are free to refuse to 
participate and may withdraw their consent at any time and for any reason during the storage 
period. A separate signature will be required to document a subject’s agreement to allow any 
remaining specimens to be used for exploratory research. Subjects who decline to participate in 
this optional research will not provide this separate signature. 
Data Protection 
• Subjects will be assigned a unique identifier by the Sponsor. Any subject records or datasets 
that are transferred to the Sponsor will contain the identifier only; subject names or any 
information which would make the subject identifiable will not be transferred. 
• The subject must be informed that his/her personal study-related data will be used by the 
Sponsor in accordance with local data protection law. The level of disclosure must also be 
explained to the subject. 
• The subject must be informed that his/her medical records may be examined by Clinical 
Quality Assurance auditors or other authorised personnel appointed by the Sponsor, by 
appropriate IEC members, and by inspectors from regulatory authorities. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 74 of 99 
• The ICF will incorporate (or, in some cases, be accompanied by a separate document 
incorporating) wording that complies with relevant data protection and privacy legislation. 
• The Sponsor or its representative will not provide individual genotype results to subjects, any 
insurance company, any employer, their family members, general physician, or any other third 
party, unless required to do so by law. 
• Extra precautions are taken to preserve confidentiality and prevent genetic data being linked 
to the identity of the subject. In exceptional circumstances, however, certain individuals might 
see both the genetic data and the personal identifiers of a subject. For example, in the case of 
a medical emergency, the Sponsor or representative physician or an investigator might know 
a subject’s identity and also have access to his or her genetic data. Also regulatory authorities 
may require access to the relevant files. 
Administrative Structure 
Table 9 
Study Administrative Structure – 3rd parties external to Sponsor 
Activities 
External Service Provider 
Study Operations Management 
Medical Monitoring 
Pivotal 
Pivotal  
Study Master File 
Pivotal 
Data Management 
IDDI 
Clinical Supply Management 
IDDI/Alcura 
Biostatistics 
IDDI 
Medical Writing 
IDDI 
Laboratory Assessments 
Local labs for safety parameters 
Covance and Pangaea labs for tumour biopsy samples 
Pharmacokinetic Sample Testing 
Accelero  
 
Dissemination of Clinical Study Data 
The results of the study should be reported within 1 year from the end of the clinical study. 
Irrespective of the outcome, the Sponsor will submit to the EU database a summary of the results 
of the clinical study within 1 year from the end of the clinical study. It shall be accompanied by a 
summary written in a manner that is understandable to laypersons. 
Data Quality Assurance 
• All subject data relating to the study will be recorded on printed or eCRFs unless transmitted 
to the Sponsor or designee electronically (eg, laboratory data). The investigator is responsible 
for verifying that data entries are accurate and correct by physically or electronically signing 
the eCRF. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 75 of 99 
• The investigator must maintain accurate documentation (source data) that supports the 
information entered in the eCRF. 
• The investigator must permit study-related monitoring, audits, IEC review, and regulatory 
agency inspections and provide direct access to source data documents. 
• The Sponsor or designee is responsible for the data management of this study including quality 
checking of the data. 
• Study monitors will perform ongoing source data verification to confirm that data entered into 
the eCRF by authorised study center personnel are accurate, complete, and verifiable from 
source documents; that the safety and rights of subjects are being protected; and that the study 
is being conducted in accordance with the currently approved protocol and any other study 
agreements, ICH GCP, and all applicable regulatory requirements. 
• Records and documents, including signed ICFs, pertaining to the conduct of this study must 
be retained by the investigator for 15 years after study completion unless local regulations or 
institutional policies require a longer retention period. No records may be destroyed during the 
retention period without the written approval of the Sponsor. No records may be transferred to 
another location or party without written notification to the Sponsor. 
Source Documents 
The investigator/institution should maintain adequate and accurate source documents and study 
records that include all pertinent observations on each of the study center’s subjects. Source data 
should be attributable, legible, contemporaneous, original, accurate, and complete. Changes to 
source data should be traceable, should not obscure the original entry, and should be explained if 
necessary (eg, via an audit trail). 
• Source documents provide evidence for the existence of the subject and substantiate the 
integrity of the data collected. Source documents are filed at the investigator’s study center. 
• Data reported on the eCRF or entered in the eCRF that are transcribed from source documents 
must be consistent with the source documents or the discrepancies must be explained. The 
investigator may need to request previous medical records or transfer records, depending on 
the study. Also, current medical records must be available. 
• Definition of what constitutes source data can be found in clinical monitoring plan. 
 
Study and Study Center Closure 
The Sponsor designee reserves the right to close the study center or terminate the study at any time 
for any reason at the sole discretion of the Sponsor. Study centers will be closed upon study 
completion. A study center is considered closed when all required documents and study supplies 
have been collected and a study center closure visit has been performed. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 76 of 99 
The investigator may initiate study center closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination. 
Reasons for the early closure of a study center by the Sponsor or investigator may include but are 
not limited to: 
• Failure of the investigator to comply with the protocol, the requirements of the IEC or local 
health authorities, the Sponsor’s procedures, or GCP guidelines. 
• Inadequate recruitment of subjects by the investigator. 
• Discontinuation of further study treatment development. 
Publication Policy 
The data generated by this study are confidential information of the Sponsor. The Sponsor will 
make the results of the study publicly available. The publication policy with respect to the 
investigator and study center will be set forth in the Clinical Trial Agreement. 
• The results of this study may be published or presented at scientific meetings. If this is foreseen, 
the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. 
This allows the Sponsor to protect proprietary information and to provide comments. 
• The Sponsor will comply with the requirements for publication of study results. In accordance 
with standard editorial and ethical practice, the Sponsor will generally support publication of 
multicenter studies only in their entirety and not as individual study center data. In this case, a 
Coordinating investigator will be designated by mutual agreement. 
• Authorship will be determined by mutual agreement and in line with International Committee 
of Medical Journal Editors authorship requirements. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 77 of 99 
Appendix 3 
Clinical Laboratory Tests 
• The tests detailed in Table 10 will be performed by the local laboratory. 
• Protocol-specific requirements for inclusion or exclusion of subjects are detailed in Section 5.0 
of the protocol. 
• Additional tests may be performed at any time during the study as determined necessary by 
the investigator or required by local regulations. 
Table 10 
Protocol-required Safety Laboratory Assessments 
Laboratory 
Assessments 
Parameters 
Haematology 
Platelet count  
RBC Indices: 
Mean corpuscular volume 
(MCV) 
Mean corpuscular 
haemoglobin (MCH) 
 
White blood cell count with 
differential: 
Neutrophils 
Lymphocytes 
Monocytes 
Eosinophils 
Basophils 
Red blood cell (RBC) count 
Haemoglobin 
Haematocrit 
Clinical 
chemistrya 
Blood urea 
nitrogen 
Potassium 
Aspartate aminotransferase 
(AST)/ Serum glutamic-
oxaloacetic transaminase 
(SGOT) 
Total and direct 
bilirubin 
 
Creatinine 
Sodium 
Alanine aminotransferase 
 (ALT)/ Serum glutamic-
pyruvic transaminase 
(SGPT) 
Total protein 
 
Glucose 
(nonfasting) 
Calcium 
Alkaline phosphatase 
GGT (gamma glutamyl 
transferase) 
 
Urine and serum 
pregnancy test 
(HCG) 
• 
At screening, within 72 hours prior to treatment, then every 6 weeks and at EOS 
Thyroid function 
test (blood) 
• 
At Visits 1a, 3, 5, 7 (Weeks 1, 7, 13, and 19) and each 6 weeks intervals 
 C-reactive 
protein (CRP)  
• 
At screening and at each visit during the treatment period and at EOS 
NOTES: Hematology, chemistry and CRP will be done at each visit during the treatment period and at EOS 
visit. In addition, if it is scheduled to administer BO-112, a coagulation test will also be done. 
a Details of liver chemistry stopping criteria and required actions and follow-up assessments after liver stopping 
or monitoring event are given in Section 7.1. All events of ALT 3 × upper limit of normal (ULN) and 
bilirubin 2 × ULN (>35% direct bilirubin) or ALT 3 × ULN and international normalised ratio (INR) >1.5, 
if INR measured, which may indicate severe liver injury (possible Hy’s Law), must be reported as an SAE 
(excluding studies of hepatic impairment or cirrhosis). 
Investigators must document their review of each laboratory safety report. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 78 of 99 
Appendix 4 
Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting 
Definition of AE 
AE Definition 
• 
An AE is any untoward medical occurrence in a patient or subject, temporally associated with the use of 
study treatment, whether or not considered related to the study treatment. 
• 
NOTE: An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease (new or exacerbated) temporally associated with the use of study 
treatment. 
 
Events Meeting the AE Definition  
• 
Any abnormal laboratory test results (haematology, clinical chemistry, or urinalysis) or other safety 
assessments (eg, ECG, radiological scans, and vital signs measurements), including those that worsen 
from baseline, considered clinically significant in the medical and scientific judgement of the 
investigator (ie, not related to progression of underlying disease). 
• 
Exacerbation of a chronic or intermittent pre-existing condition including either an increase in frequency 
and/or intensity of the condition. 
• 
New conditions detected or diagnosed after study treatment administration even though it may have been 
present before the start of the study. 
• 
Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction. 
• 
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study treatment or a 
concomitant medication. Overdose per se will not be reported as an AE/SAE unless it is an intentional 
overdose taken with possible suicidal/self-harming intent. Such overdoses should be reported regardless 
of sequelae. 
• 
"Lack of efficacy" or "failure of expected pharmacological action" per se will not be reported as an AE 
or SAE. Such instances will be captured in the efficacy assessments. However, the signs, symptoms, 
and/or clinical sequelae resulting from lack of efficacy will be reported as AE or SAE if they fulfil the 
definition of an AE or SAE. 
 
Events NOT Meeting the AE Definition  
• 
Any clinically significant abnormal laboratory findings or other abnormal safety assessments which are 
associated with the underlying disease, unless judged by the investigator to be more severe than expected 
for the subject’s condition. 
• 
The disease/disorder being studied or expected progression, signs, or symptoms of the disease/disorder 
being studied, unless more severe than expected for the subject’s condition. 
• 
Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to the procedure 
is the AE. 
• 
Situations in which an untoward medical occurrence did not occur (social and/or convenience admission 
to a hospital). 
• 
Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or detected at the 
start of the study that do not worsen. 
 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 79 of 99 
Definition of SAE 
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions 
are met (eg, hospitalisation for signs/symptoms of the disease under study, death due to 
progression of disease). 
An SAE is defined as any untoward medical occurrence that, at any dose: 
a) Results in death 
b) Is life-threatening 
The term ‘life-threatening’ in the definition of “serious” refers to an event in which the subject was at risk of 
death at the time of the event. It does not refer to an event, which hypothetically might have caused death, if 
it were more severe. 
c) Requires inpatient hospitalisation or prolongation of existing hospitalisation 
In general, hospitalisation signifies that the subject has been detained (usually involving at least an overnight 
stay) at the hospital or emergency ward for observation and/or treatment that would not have been appropriate 
in the physician’s office or outpatient setting. Complications that occur during hospitalisation are AEs. If a 
complication prolongs hospitalisation or fulfils any other serious criteria, the event is serious. When in doubt 
as to whether “hospitalisation” occurred or was necessary, the AE should be considered serious. 
Hospitalisation for elective treatment of a pre-existing condition that did not worsen from baseline is not 
considered an AE. 
d) Results in persistent disability/incapacity 
• 
The term disability means a substantial disruption of a person’s ability to conduct normal life functions. 
• 
This definition is not intended to include experiences of relatively minor medical significance such as 
uncomplicated headache, nausea, vomiting, diarrhoea, influenza, and accidental trauma (eg, sprained 
ankle) which may interfere with or prevent everyday life functions but do not constitute a substantial 
disruption. 
e) Is a congenital anomaly/birth defect 
f) 
Other situations: 
• 
Medical or scientific judgement should be exercised in deciding whether SAE reporting is appropriate 
in other situations such as important medical events that may not be immediately life-threatening or 
result in death or hospitalisation but may jeopardise the subject or may require medical or surgical 
intervention to prevent 1 of the other outcomes listed in the above definition. These events should usually 
be considered serious. 
Examples of such events include invasive or malignant cancers, intensive treatment in an emergency 
room or at home for allergic bronchospasm, blood dyscrasias, or convulsions that do not result in 
hospitalisation, or development of drug dependency or drug abuse. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 80 of 99 
Recording and Follow-up of AE and/or SAE 
AE and SAE Recording 
• 
When an AE/SAE occurs, it is the responsibility of the investigator to review all documentation (eg, 
hospital progress notes, laboratory reports, and diagnostics reports) related to the event. 
• 
The investigator will then record all relevant AE/SAE information in the eCRF. Each event must be 
recorded separately. 
• 
It is not acceptable for the investigator to send photocopies of the subject’s medical records to Highlight 
Therapeutics in lieu of completion of the BOT112-02/AE/SAE eCRF page. 
• 
There may be instances when copies of medical records for certain cases are requested by Highlight 
Therapeutics. In this case, all subject identifiers, with the exception of the subject number, will be 
redacted on the copies of the medical records before submission to Highlight Therapeutics. 
• 
The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other 
clinical information. Whenever possible, the diagnosis (not the individual signs/symptoms) will be 
documented as the AE/SAE. 
Assessment of Intensity 
The investigator will make an assessment of intensity for each AE and SAE reported during the study and 
assign it to 1 of the following categories: 
• 
Mild: An event that is easily tolerated by the subject, causing minimal discomfort and not interfering 
with everyday activities. 
• 
Moderate: An event that causes sufficient discomfort and interferes with normal everyday activities. 
• 
Severe: An event that prevents normal everyday activities. An AE that is assessed as severe should not 
be confused with an SAE. Severe is a category utilised for rating the intensity of an event; and both AEs 
and SAEs can be assessed as severe. 
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as described in the 
definition of an SAE, NOT when it is rated as severe. 
• 
National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0 will 
be used for severity grading. 
 
Assessment of Causality 
• 
The investigator is obligated to assess the relationship between study treatment and each occurrence of 
each AE/SAE. The AE must be characterised as unrelated, unlikely to be related, possibly related, 
probably related, or unknown (unable to judge). 
o 
“Probably related” conveys that there are facts, evidence, and/or arguments to suggest a causal 
relationship, rather than a relationship cannot be ruled out. 
o 
“Possibly related” suggests that the association of the AE with the study treatment is unknown; 
however, the AE is not reasonably supported by other conditions. 
o 
“Unlikely to be related” suggests that only a remote connection exists between the study 
treatment and the AE. Other conditions, including chronic illness, progression or expression of 
the disease-state or reaction to concomitant therapy, appear to explain the reported AE. 
o 
“Unrelated” is used if there is not a reasonable possibility that the study treatment caused the 
AE. 
o 
All efforts should be made to classify the AE according to the above categories. The category 
“unknown” (unable to judge) may be used only if the causality is not assessable, eg, because of 
insufficient evidence, conflicting evidence, conflicting data, or poor documentation. 
• 
The investigator will use clinical judgement to determine the relationship. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 81 of 99 
• 
Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as well as 
the temporal relationship of the event to study treatment administration will be considered and 
investigated. 
• 
The investigator will also consult the Investigator’s Brochure and/or Product Information, for marketed 
products, in his/her assessment. 
• 
For each AE/SAE, the investigator must document in the medical notes that he/she has reviewed the 
AE/SAE and has provided an assessment of causality. 
• 
There may be situations in which an SAE has occurred, and the investigator has minimal information to 
include in the initial report to appropriate regulatory authorities. However, it is very important that the 
investigator always make an assessment of causality for every event before the initial transmission of 
the SAE data to appropriate regulatory authorities. 
• 
The investigator may change his/her opinion of causality in light of follow-up information and send an 
SAE follow-up report with the updated causality assessment. 
• 
The causality assessment is one of the criteria used when determining regulatory reporting requirements. 
 
Follow-up of AEs and SAEs 
• 
The investigator is obligated to perform or arrange for the conduct of supplemental measurements and/or 
evaluations as medically indicated or as requested by Highlight Therapeutics to elucidate the nature 
and/or causality of the AE or SAE as fully as possible. This may include additional laboratory tests or 
investigations, histopathological examinations, or consultation with other health care professionals. 
• 
If a subject dies during participation in the study or during a recognised follow-up period, the investigator 
will provide Highlight Therapeutics with a copy of any postmortem findings including histopathology. 
• 
New or updated information will be recorded in the originally completed eCRF. 
• 
The investigator will submit any updated SAE data to Highlight Therapeutics, S.L within 24 hours of 
receipt of the information. 
 
Reporting of SAEs 
SAE Reporting to appropriate regulatory authorities 
• 
Please follow the adverse event and serious adverse event guidelines. 
 
 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 82 of 99 
Appendix 5 
Excluded Medications/Therapy 
Excluded medications/therapy is listed below. The use of an excluded medication/therapy is a 
protocol violation and must be recorded in the eCRF. 
• Chemotherapy, definitive (curative) radiation, or biological cancer therapy within 4 weeks 
prior to the first dose of study treatment and during the study. 
• Palliative radiotherapy (≤ 2 weeks of radiotherapy) within 1 week of start of study treatment. 
Palliative radiotherapy during the study may be allowed and should be discussed with the 
Sponsor. Lesions which receive palliative radiotherapy will be considered not evaluable as of 
the first day of the radiotherapy. 
• Corticosteroids at physiologic doses exceeding 10 mg/day of prednisone or equivalent prior to 
start of treatment. Corticosteroid therapy is allowed during the study for the treatment of 
immune-related adverse events (See Section 1.1). 
• Contraindications to tumour biopsy and injections of the hepatic metastasis(es), such as 
coagulopathy, therapeutic dose anticoagulant treatment and treatment with long-acting agents 
such as clopidogrel which cannot be safely stopped. 
• Another investigational agent or device. 
 
 
 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 83 of 99 
Appendix 6: Description of the iRECIST Process for Assessment of Disease 
Progression 
Assessment at Screening and Prior to RECIST 1.1 Progression 
Until radiographic disease progression based on RECIST 1.1, there is no distinct iRECIST 
assessment. 
Assessment and Decision at RECIST 1.1 Progression 
For subjects who show evidence of radiological PD by RECIST 1.1 as determined by the 
investigator, the investigator will decide whether to continue a subject on study treatment until 
repeat imaging is obtained (using iRECIST for subject management; see Table 6). This decision 
by the investigator should be based on the subject’s overall clinical condition. 
Clinical stability is defined as the following: 
• Absence of symptoms and signs indicating clinically significant progression of 
disease 
• No decline in ECOG performance status 
• No requirements for intensified management, including increased analgesia or 
other palliative care. In case of need for palliative radiotherapy, possible 
treatment continuation should be discussed with Sponsor. 
Any subject deemed clinically unstable should be discontinued from study treatment at site-
assessed first radiologic evidence of PD and is not required to have repeat tumour imaging for 
confirmation of PD by iRECIST. 
If the investigator decides to continue treatment, the subject may continue to receive study 
treatment and the tumour assessment should be repeated 4-6 weeks later to confirm PD by 
iRECIST, per investigator assessment. 
Tumour flare may manifest as any factor causing radiographic progression per RECIST 1.1, 
including: 
• Increase in the sum of diameters of target lesion(s) identified at baseline to ≥ 20% and 
≥ 5 mm from nadir 
o Note: the iRECIST publication uses the terminology “sum of measurements”, but 
“sum of diameters” will be used in this protocol, consistent with the original 
RECIST 1.1 terminology. 
• Unequivocal progression of non-target lesion(s) identified at baseline 
• Development of new lesion(s) 
iRECIST defines new response categories, including iUPD (unconfirmed progressive disease) and 
iCPD (confirmed progressive disease). For purposes of iRECIST assessment, the first visit 
showing progression according to RECIST 1.1 will be assigned a visit (overall) response of iUPD, 
regardless of which factors caused the progression. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 84 of 99 
At this visit, target and non-target lesions identified at baseline by RECIST 1.1 will be assessed as 
usual. 
New lesions will be classified as measurable or non-measurable, using the same size thresholds 
and rules as for baseline lesion assessment in RECIST 1.1. From measurable new lesions, up to 
5 lesions total (up to 2 per organ), may be selected as new lesions – Target. The sum of diameters 
of these lesions will be calculated and kept distinct from the sum of diameters for target lesions at 
baseline. All other new lesions will be followed qualitatively as new lesions – nontarget. 
Assessment at the Confirmatory Imaging 
On the confirmatory imaging, the subject will be classified as progression confirmed (with an 
overall response of iCPD), or as showing persistent unconfirmed progression (with an overall 
response of iUPD), or as showing disease stability or response (iSD/iPR/iCR). 
Confirmation of Progression 
Progression is considered confirmed, and the overall response will be iCPD, if ANY of the 
following occurs: 
• Any of the factors that were the basis for the initial iUPD show worsening 
o For target lesions, worsening is a further increase in the sum of diameters of ≥5 mm, 
compared to any prior iUPD time point 
o For non-target lesions, worsening is any significant growth in lesions overall, compared 
to a prior iUPD time point; this does not have to meet the “unequivocal” standard of 
RECIST 1.1 
o For new lesions, worsening is any of these: 
▪ An increase in the new lesion sum of diameters by ≥5 mm from a prior iUPD time 
point 
▪ Visible growth of new non-target lesions 
▪ The appearance of additional new lesions 
• Any new factor appears that would have triggered PD by RECIST 1.1 
Persistent iUPD 
Progression is considered not confirmed, and the overall response remains iUPD, if: 
• None of the progression-confirming factors identified above occurs AND 
• The target lesion sum of diameters (initial target lesions) remains above the initial PD 
threshold (by RECIST 1.1) 
Additional imaging for confirmation should be scheduled 4 to 8 weeks from the imaging on which 
iUPD is seen. This may correspond to the next visit in the original visit schedule. The assessment 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 85 of 99 
of the subsequent confirmation imaging proceeds in an identical manner, with possible outcomes 
of iCPD, iUPD, and iSD/iPR/iCR. 
Resolution of iUPD 
Progression is considered not confirmed, and the overall response becomes iSD/iPR/iCR, if: 
• None of the progression-confirming factors identified above occurs, AND 
• The target lesion sum of diameters (initial target lesions) is not above the initial PD 
threshold. 
The response is classified as iSD or iPR (depending on the sum of diameters of the target lesions), 
or iCR if all lesions resolve. 
In this case, the initial iUPD is considered to be pseudo-progression, and the level of suspicion for 
progression is “reset”. This means that the next visit that shows radiographic progression, 
whenever it occurs, is again classified as iUPD by iRECIST, and the confirmation process is 
repeated before a response of iCPD can be assigned. 
Management Following the Confirmatory Imaging 
If repeat imaging does not confirm PD per iRECIST, as assessed by the investigator, and the 
subject continues to be clinically stable, study treatment may continue and follow the regular 
imaging schedule. If PD is confirmed, subjects will be discontinued from study treatment. 
NOTE: If a subject has confirmed radiographic progression (iCPD) as defined above, but the 
subject is achieving a clinically meaningful benefit, an exception to continue study treatment may 
be considered following consultation with the Sponsor. In this case, if study treatment is continued, 
tumour imaging should continue to be performed following the scheduled intervals. 
Detection of Progression at Visits After Pseudo-progression Resolves 
After resolution of pseudo-progression (ie, achievement of iSD/iPR/iCR), iUPD is indicated by 
any of the following events: 
• Target lesions 
o Sum of diameters reaches the PD threshold (≥20% and ≥5 mm increase from nadir) 
either for the first time, or after resolution of previous pseudo-progression. The 
nadir is always the smallest sum of diameters seen during the entire study, either 
before or after an instance of pseudo-progression. 
• Non-target lesions 
o If non-target lesions have never shown unequivocal progression, their doing so for 
the first time results in iUPD. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 86 of 99 
o If non-target lesions have shown previous unequivocal progression, and this 
progression has not resolved, iUPD results from any significant further growth of 
non-target lesions, taken as a whole. 
• New lesions 
o New lesions appear for the first time 
o Additional new lesions appear 
o Previously identified new target lesions show an increase of ≥ 5 mm in the new 
lesion sum of diameters, from the nadir value of that sum 
o Previously identified non-target lesions show any significant growth 
If any of the events above occur, the overall response for that visit is iUPD, and the iUPD 
evaluation process (see Assessment at the Confirmatory Imaging above) is repeated. Progression 
must be confirmed before iCPD can occur. 
The decision process is identical to the iUPD confirmation process for the initial PD, with 1 
exception: if new lesions occurred at a prior instance of iUPD, and at the confirmatory imaging 
the burden of new lesions has increased from its smallest value (for new target lesions, the sum of 
diameters is ≥5 mm increased from its nadir), then iUPD cannot resolve to iSD or iPR. It will 
remain iUPD until either a decrease in the new lesion burden allows resolution to iSD or iPR, or 
until a confirmatory factor causes iCPD. 
Additional details about iRECIST are provided in the iRECIST publication. 
 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 87 of 99 
Appendix 7 
Contraceptive Guidance and Collection of Pregnancy 
Information 
Definitions: 
Woman of Childbearing Potential (WOCBP) 
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanently sterile (see below). 
Women in the following categories are not considered WOCBP 
1. Premenarchal 
2. Premenopausal female with 1 of the following: 
a) Documented hysterectomy. 
b) Documented bilateral salpingectomy. 
c) Documented bilateral oophorectomy. 
Note: Documentation can come from the study center personnel’s: review of the subject’s 
medical records, medical examination, or medical history interview. 
3. Postmenopausal female: 
a) A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal 
range may be used to confirm a postmenopausal state in women not using hormonal 
contraception or hormonal replacement therapy (HRT). However, in the absence of 
12 months of amenorrhea, a single FSH measurement is insufficient. 
b) Females on HRT and whose menopausal status is in doubt will be required to use 1 of the 
non-oestrogen hormonal highly effective contraception methods if they wish to continue 
their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation 
of postmenopausal status before study enrolment. 
Contraception Guidance 
Female subjects 
Female subjects of childbearing potential are eligible to participate if they agree to use a highly 
effective method of contraception consistently and correctly as described in the table below. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 88 of 99 
Highly Effective Contraceptive Methods 
Highly Effective Contraceptive Methods That Are User Dependent a 
Failure rate of < 1% per year when used consistently and correctly.  
Combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulationb 
• 
Oral. 
• 
Intravaginal. 
• 
Transdermal. 
Progestogen only hormonal contraception associated with inhibition of ovulation 
• 
Oral. 
• 
Injectable.  
Highly Effective Methods That Are User Independent a  
Implantable progestogen only hormonal contraception associated with inhibition of ovulation 
• 
Intrauterine device (IUD). 
• 
Intrauterine hormone-releasing system (IUS). 
Bilateral tubal occlusion. 
Vasectomised Partner 
A vasectomised partner is a highly effective birth control method provided that the partner is the sole male sexual 
partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method of 
contraception should be used.  
Sexual Abstinence 
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence 
needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the subject.  
NOTES: 
a Typical use failure rates may differ from those when used consistently and correctly. Use should be consistent with 
local regulations regarding the use of contraceptive methods for subjects participating in clinical studies. 
 
Pregnancy Testing: 
• WOCBP should only be included after a confirmed menstrual period and a negative highly 
sensitive serum pregnancy test. 
• Additional pregnancy testing should be performed at time points specified in the Schedule of 
Assessments during the treatment period and at the EOS visit (28 days after the last dose of 
study treatment) and as required locally. 
Pregnancy testing will be performed whenever a menstrual cycle is missed or when pregnancy is 
otherwise suspected. 
• Pregnancy testing, with a sensitivity of 5, 10, or 25 mIU/mL will be performed and assayed 
in a certified laboratory. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 89 of 99 
Collection of Pregnancy Information 
Female Subjects who become pregnant 
• The investigator will collect pregnancy information on any female subject who becomes 
pregnant while participating in this study. Information will be recorded on the appropriate 
form and submitted to the Sponsor within 24 hours of learning of a subject’s pregnancy. The 
subject will be followed to determine the outcome of the pregnancy. The investigator will 
collect follow-up information on the subject and the neonate and the information will be 
forwarded to the Sponsor. Generally, follow-up will not be required for longer than 6 to 
8 weeks beyond the estimated delivery date. Any termination of pregnancy will be reported, 
regardless of fetal status (presence or absence of anomalies) or indication for the procedure. 
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or 
elective termination of a pregnancy will be reported as an AE or SAE. A spontaneous 
abortion is always considered to be an SAE and will be reported as such. 
• Any post-study pregnancy related SAE considered reasonably related to the study treatment 
by the investigator will be reported to the Sponsor as described in Section 8.3.4. While the 
investigator is not obligated to actively seek this information in former subjects, he or she 
may learn of an SAE through spontaneous reporting. 
• Any female subject who becomes pregnant while participating in the study will discontinue 
study treatment or be withdrawn from the study. 
Continuation of study treatment may only be allowed if either of the following criteria is met: 
The study treatment has an approved label that indicates it can be used safely in pregnant 
females. 
OR 
All of the following apply: 
• The subject has a high mortality disease. 
• The investigator determines the subject is benefitting from study participation and there is no 
other reasonable treatment for her. 
• The Sponsor and the relevant IEC give written approval. 
• The subject gives signed informed consent. 
• The investigator agrees to monitor the outcome of the pregnancy and the status of the subject 
and her offspring. 
• The protocol is amended to allow such participation on a case-by-case basis, if such 
participation is not already addressed in the protocol. 
 
 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 90 of 99 
Appendix 8 
Eastern Cooperative Oncology Group (ECOG)Performance 
Status 
Grade 
Description 
0 
Fully active, able to carry on all pre-disease performance without restriction 
1 
Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature, ie, light house work, office work 
2 
Ambulatory and capable of all self-care but unable to carry out any work activities. Up and 
about more than 50% of waking hours 
3 
Capable of only limited self-care, confined to bed or chair more than 50% of waking hours 
4 
Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair 
5 
Dead 
For detail, see Oken et al., 1982 (Reference 37) 
 
 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 91 of 99 
Appendix 9     Recommendations for cancer patient management in the 
protocol BOT112-02 during SARS-CoV-2 pandemic 
1-Introduction 
Coronaviruses are a group of highly diverse RNA viruses in the Coronaviridae family that are 
divided in 4 genera: alpha, beta, gamma and delta that cause disease varying from mild to severe 
in human and animals. However, two zoonotic coronaviruses have emerged causing severe disease 
in humans: Severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002-2003 and Middle 
East respiratory syndrome coronavirus (MERS-CoV) (1). In January 2020, the etiologic agent 
responsible for a cluster of severe pneumonia cases in Wuhan, China, was identified as being a 
novel betacoronavirus, distinct from SARS-CoV and MERS-CoV. On 11 February 2020, the 
International Committee on Taxonomy of Viruses (ICTV) announced that the virus was named 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (2) while, on the same day, WHO 
named the disease as coronavirus disease COVID-19 (3). 
The evolution of COVID-19 infection is different to other viruses of the coronavirus family, with 
a case fatality rate of 1.5-12.3% based on the reporting country, and a worst evolution in older 
patients. At this moment, a pandemic situation is ongoing and knowledge and recommendations 
on the management of this illness and its relationship with cancer are in progress. However, there 
are certain recommendations that it is advisable to follow whenever the resources of the institutions 
allow, including  recommendations regarding the precautions to be taken at enrollment to avoid 
including in this trial patients infected by COVID-19 and during the treatment period, to reduce 
risks of infection and describe how to manage the patients in case on infection. These 
recommendations should be used as guidance for prioritizing the various aspects of cancer care in 
order to mitigate the negative effects of the COVID-19 pandemic on the management of cancer 
patients in this trial. The situation is evolving, and pragmatic actions may be required to deal with 
the challenges of treating patients, while ensuring their rights, safety and wellbeing. 
1-1 Clinical manifestations 
The percentage of infected people by Covid-19 who are asymptomatic or oligosymptomatic in the 
general population is currently unknown. These uncertainties are also referring to the prevalence 
of asymptomatic disease in cancer patients. So far, no systematic reports are available regarding a 
higher incidence of COVID-19 asymptomatic infections in patients with cancer. Recent limited 
data from China, and more recently from Italy and the US, do however seem to confirm a higher 
risk. 
When clinical manifestations are present, the most frequent symptoms include fever and persistent 
cough, with some subjects having dyspnea, sore throat, headache and diarrhea.  Another possible 
symptoms related to COVID-19 infection are muscle pain, tiredness, anosmia and dysgeusia. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 92 of 99 
In contrast to severe acute respiratory insufficiency related to other coronavirus, more deaths from 
COVID-19 have been caused by multiple organ dysfunction syndrome rather than respiratory 
failure, which might be attributable to the widespread distribution of angiotensin converting 
enzyme 2—the functional receptor for COVID-19—in multiple organs (4). 
Males may be affected more severely than females, however most patients (80%) have relatively 
mild, influenza-like symptoms and achieve full recovery within 10 days. Available data indicate 
that older people are more vulnerable, with underlying health conditions such as chronic 
respiratory, cardio-vascular or chronic kidney disease, diabetes, active cancer and more generally 
severe chronic diseases (5-7). 
Cancer patients seem to be at higher risk of infection with COVID-19 because of the immune 
system impairment related to malignancy and anticancer treatments. More concerning is the 
increased risk of severe respiratory complications requiring time in the intensive care unit in 
patients with cancer, as compared with patients without cancer (39% vs 8%, respectively; 
p=0.0003), as described in a recently published nationwide analysis conducted by the National 
Clinical Research Center for Respiratory Disease in China (4), which included a  prospective 
cohort to monitor COVID-19 cases throughout the country. As of the data cutoff on Jan 31, 2020, 
a total of 2007 cases had collected and analyzed from 575 hospitals. From them, 18 cancer patients 
were identified in this cohort. Compared with patients without cancer, patients with cancer were 
older (63.1 years vs 48.7 years), more likely to have a history of smoking, had more polypnea and 
more severe baseline CT manifestation, but had no significant differences in sex, other baseline 
symptoms, other comorbidities, or baseline severity of x-ray. Patients with cancer were observed 
to have a higher risk of severe events (percentage of patients being admitted to the intensive care 
unit requiring invasive ventilation, or death) compared with patients without cancer (39% cancer 
patient vs 8%non-cancer patients; p=0·0003). Cancer history represented the highest risk for 
severe events in this study. Additionally, patients with cancer deteriorated more rapidly than those 
without cancer (median time to severe events 13 days vs 43 days; p<0·0001; hazard ratio 3.56, 
95% CI 1.65–7.69). 
In this context, the possible impact that immunomodulatory treatments could have in the risk of 
infection by COVID-19 and the intensity of the clinical manifestations is not known. Therefore, 
during this pandemic, the benefit/risk ratio of cancer treatment need to be reconsidered. 
1-2 Diagnosis 
1-2-1 Molecular methods 
Routine confirmation of COVID-19 cases is based on detection of its nucleic acid (RNA) by real 
time RT-PCR assays. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 93 of 99 
RT-PCR on respiratory samples is the “gold standard” technique for COVID-19 diagnosis. 
Recommended samples are those from the lower respiratory tract, including sputum, 
bronchoalveolar lavage and tracheal aspirate (when possible according to medical criteria). 
However, when collection of a lower respiratory tract sample is not possible, samples from the 
upper respiratory tract are also useful. In general, the collection of a combined nasopharyngeal 
swab and oropharyngeal swab is recommended (8) 
This technique has a high specificity; thus, a positive result confirms the detection of the virus. On 
the contrary, a negative result might not always mean the absence of COVID-19 virus infection. 
Several reasons might explain a negative result in a person infected with COVID-19 virus, mainly:  
• 
Poor sample quality, handling, transportation and/or storage.  
• 
Poor/failed sample extraction, presence of PCR inhibitors in the extracted RNA.  
• 
The sample was collected at a time where the patient was not shedding sufficient amounts 
of virus, for instance very early or very late during infection (this point is particularly 
relevant as the dynamics of the viral presence in different sample types has not been fully 
established). 
• 
As with any molecular detection assay, virus mutations in the regions that are targeted by 
the assays might affect the sensitivity of the detection. 
Therefore, in case of having a negative RT-PCR result in a patient who has been in contact with a 
confirmed case or who has suggestive clinical manifestations, the COVID-19 testing should be 
repeated. 
The limitations of this method are that while it confirms the presence of viral RNA, it does not 
detect prior infection or immunity to future infection. However, it is currently assumed that PCR 
positive asymptomatic persons have the risk of infecting (it is believed that between 30-50% of 
infections occur through asymptomatic individuals) and/or develop symptoms later.  
1-2-2 Serological methods 
Several assays (both ELISA and rapid diagnostic tests) are available for the detection of IgM/IgG 
antibodies and are marketed for the detection of COVID-19 virus infections. 
These tests may be limited due to cross-reactivity with other coronaviruses that are normally 
present in the community and that make the interpretation of results difficult (9). 
Antigen detection 
During the first days after symptom onset (approximately 1 to 5), viral proteins are generated and 
can be detected by different tests (eg, ELISA, immunofluorescence).  

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 94 of 99 
Rising IgM levels can be detected from approx. day 3-7 since the infection by COVID-19, with a 
maximum of 14 days, and frequently coincides with the presence of first clinical manifestations. 
The maximum levels being detected 8-14 days since the clinical manifestations start date. 
Secretion of IgG antibodies occurs between days 5-7 after the onset of symptoms. On average, the 
maximum IgG value is reached between days 10-14.  
The detection of an immune response to COVID-19 by serology evaluation allows an 
understanding of who has been exposed (and been infected) and the degree to which these 
individuals may have some immunity to future infections. Comparing to RT-PCR, this is a cheaper 
and more simple technique.  
In general, this type of assays has acceptable specificity. In confirmed and probable cases, the 
efficiency of detection by IgM is greater than that of PCR after 5.5 days of symptom onset. 
Nevertheless, a negative result (at any stage of infection) should not be used as a criterion to rule 
out a case, and therefore other criteria must be taken into account. Positive detection rate 
increases significantly (98.6%) when combining IgM with RT- PCR for each patient 
compared to a single test (10). 
Rapid serologic tests 
In general, these types of tests have low sensitivity. Therefore, their positive predictive value is 
good (they can be used to rule in cases), but their negative predictive value is low (they should not 
be used to rule out cases). 
2- Recommendations to be considered in regards of patients´ eligibility and management 
during the trial. 
2-1 COVID-19 infection diagnosis 
Based on ESMO´s guidelines for management of cancer patients during COVID-19 pandemic (11) 
the following diagnostic procedures should be considered to confirm the diagnosis of COVID-19 
infection in this trial: 
• RT-PCR testing should be proposed to all potential patients for this trial within the close 
previous days before submitting the eligibility package. If feasible for each concrete site, and 
ideally, it should be repeated before each treatment/cycle. 
In addition, this test should also be proposed to patients during the treatment period in the trial 
if they present with symptoms clearly suggestive of COVID-19 infection. In this sense, all 
patients should be actively asked about the presence of clinical manifestations related to 
COVID-19 infection by the investigator in ALL visits during the pandemic. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 95 of 99 
• Serology (ELISA), if available, should be considered to be proposed to identify previous 
COVID-19 infection in all cancer patients in the trial at screening and, during treatment period, 
in all those patients with clinical manifestations suggestive of COVID-19 infection or close 
positive cases. Performing a serology testing  could provide  us with useful information to 
differentiate patients with high IgG and little risk of developing the disease, and those patients  
with high IgM who haves not yet started to develop symptoms and ideally must be studied 
before the inclusion. 
• Ideally, patients should be tested using both techniques, especially those patients with negative 
IgG and IgM, or with high IgM, although this will be based on the countries and sites´ 
resources. If only one technique can be done, PCR should be recommended.  
2-2 Management of patients with a suspected/confirmed COVID-19 infection. 
• Screening period: For patients who are exhibiting symptoms consistent with COVID-19 or 
have tested positive, enrollment and protocol treatment should not be initiated. After the 
infection resolution and test negativity, the possibility of enrolment must be discussed case by 
case with the sponsor Medical Monitor.  
• Treatment period: For patients who have a confirmed COVID-19 infection, the decision 
about having the treatment on hold or not must be discussed case by case with the sponsor 
Medial Monitor. 
2-3 Patients´ visits to the sites 
During the COVID-19 pandemic, the duration of the time that the patients spend on the hospital 
should be reduced as much as possible in order to decrease the probability of infection. Patients 
should be asked to take all precautionary measures (wearing a face mask, gloves, keeping social 
distancing…) In addition to that, the investigator should specifically ask the patients about the 
presence of clinical manifestations suggestive of COVID-19 infection. In this sense, please 
consider the following recommendations for patients in the trial having fever and/or respiratory 
symptoms: 
• These patients shouldn´t be evaluated in oncology day centers. 
• Initial evaluation outside of the area with high concentration of cancer patients or oncology 
staff. 
• Possibility of coronavirus must be considered and evaluated in cancer patients with fever. 
• Consider limiting points of entry to the facility. 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 96 of 99 
• Take steps to ensure that all the patients  with symptoms of respiratory infection adhere to 
respiratory hygiene and cough etiquette, hand hygiene, and triage procedures.  
o Post visual alerts icon (e.g., signs, posters) at the entrance and in strategic places 
(e.g., waiting areas, elevators, cafeterias) to provide patients with instructions about 
hand hygiene and respiratory hygiene.  
o Provide supplies for respiratory hygiene and cough etiquette, including alcohol-
based hand rub (ABHR) with 60-95% alcohol, tissues, and no-touch receptacles for 
disposal, at healthcare facility entrances, waiting rooms, and patient check-ins. 
o Install physical barriers at the reception areas to limit close contact between triage 
personnel and potentially infectious patients. 
• 
Ensure rapid safe triage and isolation of patients with symptoms of suspected COVID-19 
or other respiratory infection.  
o Prioritize assistance of patients with respiratory symptoms. 
o Triage personnel should have a supply of facemasks and tissues for patients with 
symptoms of respiratory infection. These should be provided to patients with 
symptoms of respiratory infection at check-in. 
o Isolate the patient in an examination room with the door closed. If an examination 
room is not readily available ensure the patient is not allowed to wait with other 
patients seeking care.  
o Identify a separate, well-ventilated space that allows waiting patients to be 
separated by 2 meters, with easy access to respiratory hygiene supplies. 
2-4- Specific treatment for COVID-19 
Currently there is no conventional treatment for COVID-19 in addition to supportive treatment. It 
is therefore not possible to provide any specific recommendations since most of the treatments 
currently used are based on laboratory data: chloroquine, hydroxychlorocin, anti IL6 antibodies, 
etc.  
In any case, patients should be treated according to the general criteria of the care centers with the 
resources and means they currently have. Age, comorbidity and life expectancy should be 
considered. 
2-5 Protocol procedures  
According to EMA guidance on the management of clinical trials during the COVID-19 pandemic 
(12), prospective protocol waivers remain unacceptable and all efforts should be done to follow 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 97 of 99 
the trial protocol. Nevertheless, patients´ safety and welfare should always prevail. In case of 
protocol deviations, the classification defined in the Protocol Deviation Plan for this trial will be 
followed. 
In this trial there are some critical laboratory tests, imaging and other diagnostic tests to be 
performed, (e.g. blood cell count, liver function test, CT, MRI, ECG etc.), e.g. for trial patient´s 
safety and the integrity of the trial. In case the patient in this trial cannot reach the site to have 
these performed because of the COVID-19 pandemic, it could be acceptable that laboratory, 
imaging or ECG tests be done at a local laboratory or relevant clinical facility authorised/certified 
(as legally required nationally) to perform such tests in these exceptional situations, if this can be 
done within local restrictions on social distancing. The sites should inform the sponsor about such 
cases as soon as they be aware of these situations and ask for approval. In these cases, it is 
important that the sponsor is given access to the normal ranges and certification information of 
any additional laboratory used in order to support the use and evaluation of results. 
2-6 Safety reporting 
Sponsors are expected to continue safety reporting in adherence to EU and national legal 
frameworks. When per protocol physical visits are reduced or postponed, it is important that the 
investigators continue collecting adverse events from the trial participant through alternative 
means, e.g phone calls. 
At this moment, it is not clear that antineoplastic (mostly immunomodulators) treatments have a 
special influence on COVID-19 infection over other viruses or vice versa, so for relation 
assignment it does not seem logical to use criteria other than those previously used.  
2-7 Data verification 
Whenever possible, data verification will be done by physically visiting the site. Nevertheless, in 
case of mobility limitations due to the COVID-19 pandemic, remote monitoring visits and data 
verification will be allowed.  
2-8 Audits 
During this pandemic, audits will only be conducted if permitted under national, local and/or 
organizational social distancing restrictions stablished to control COVID-19 pandemic.  
 
 
 
 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 98 of 99 
REFERENCES 
1- Korsman S et al. Human Coronaviruses. Virology 2012. Pub. Churchill Livingstone. 
2- 
Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. Severe acute respiratory syndrome-related coronavirus: 
The species and its viruses – a statement of the Coronavirus Study Group. bioRxiv. 2020:2020.02.07.937862. 8.  
3- World Health Organization. Naming the coronavirus disease (COVID-19) and the virus that causes it. Geneva: WHO; 2020 Available from: 
https://www.who.int/emergencies/diseases/novel-coronavirus2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-
the-virus-that-causes-it. 
4- 
The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. Vital Surveillances: The Epidemiological Characteristics of 
an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. China CDC Weekly 2020; 2: 113-122. 
5- 
Spadaro S et al. Biomarkers for Acute Respiratory Distress syndrome and prospects for personalised medicine. Journal of Inflammation 2019; 
16:1. 
6- 
Gao Y et al. Diagnostic Utility of Clinical Laboratory Data Determinations for Patients with the Severe COVID-19. J Med Virol 2020. 
https://doi.org/10.1002/jmv.25770 
7- 
Gralinski LE et al. Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis. mBio 2018; 9: 
1753-18. https://doi org/10.1128/mBio.01753-18. 
8- 
Pan American Health Organization / World Health Organization Laboratory Guidelines for the Detection and Diagnosis of COVID-19 
Virus Infection. Washington, DC: PAHO / WHO; 2020. Available from:  https://www.paho.org/en/documents/laboratory-guidelines-
detection-and-diagnosis-covid-19-virus-infection 
9- 
Guo L, Ren L, Yang S, Xiao M, Chang, Yang F, et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-
19). Clin Infect Dis. 2020 Mar 21. pii: ciaa310. 
10- Meyer B, Drosten C, Muller MA. Serological assays for emerging coronaviruses: challenges and pitfalls. Virus Res. 2014;194:175-83. 
11- ESMO 
guidelines. 
Cancer 
patient 
management 
during 
Covis-19 
pandemic. 
Lugano; 
2020. 
Available 
from: 
https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic?page=2. 
12- European Medicines Agency. Guidance on the management of clinical trials during the covid-19 (coronavirus) pandemic. Brussel: 2020. 
Available from: https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-10/guidanceclinicaltrials_covid19_en.pdf 
 

CONFIDENTIAL 
Protocol BOT112-02 – v2.2, 15 Oct 2021 
 
Page 99 of 99 
Appendix 10 
Signature of Investigator 
PROTOCOL TITLE: 
Phase IIa open-label clinical study of intratumoural administration of BO-112 in combination 
with pembrolizumab in subjects with liver metastasis from colorectal cancer or gastric/gastro-
esophageal junction cancer. 
PROTOCOL NO: 
BOT112-02 
VERSION:  
 
Amendment 1 Version 2.1 
This protocol is a confidential communication of Highlight Therapeutics, S.L. I confirm that I have 
read this protocol, I understand it, and I will work according to this protocol. I will also work 
consistently with the ethical principles that have their origin in the Declaration of Helsinki and that 
are consistent with Good Clinical Practices and the applicable laws and regulations. Acceptance 
of this document constitutes my agreement that no unpublished information contained herein will 
be published or disclosed without prior written approval from the Sponsor. 
Instructions to the Investigator: Please SIGN and DATE this signature page. PRINT your name, title, and the name of the study 
center in which the study will be conducted. Return the signed copy to Pivotal. 
 
I have read this protocol in its entirety and agree to conduct the study accordingly: 
 
Signature of Investigator:  
__________________________ Date: ________ 
Printed Name: ___________________________ 
Investigator Title: ___________________________ 
 
Name/Address of Center:  
___________________________ 
 
 
 
 
___________________________ 
 
 
 
 
___________________________